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Abstract of Thesis
The principle of male hormonal contraception has been investigated for the past 20 years.
This thesis reviews what is known already from the literature and presents the results of
three new clinical trials investigating different aspects of this approach.
These trials were undertaken by myself as a member of the Contraceptive Development
Network research group at the University of Edinburgh.
MOIS: A clinical trial of male hormonal contraception with a treatment period of 48
weeks. Subjects (n=29) were randomised to receive either 2 MENT Ac implants or
600mg per 12 weeks testosterone pellets in conjunction with 2 etonogestrel implants and
outcome measures of sperm count, and reproductive hormone data were collected to
assess contraceptive effects. Haematology and biochemistry parameters, prostate volume,
PSA, bone density and blood pressure measurements were recorded to assess safety and
the effects on androgen dependent tissues. The spermatogenic suppression achieved was
similar and effective in both groups. Thereafter, the MENT group failed to maintain
suppression and 6 men nnoted loss of libido due to a decline in the release rate of the
MENT implants. No adverse effects of MENT on the prostate or bone mass were
demonstrated. A small but significant increase in systolic blood pressure was observed in
the MENT group and the implications of this remain to be further qualified. In the
testosterone group profound and consistent spermatogenic suppression was demonstrated
and azoospermia was achieved in all men. An increase in haemoglobin and prostate size
and reduction in HDL-C were noted. MENT with progestogen can achieve rapid
i
suppression of spermatogenesis similar to testosterone, but this promising result was not
sustained due to a reduction in the MENT release from the implants. This dose of
testosterone, compared with previous studies using lower dose with a higher dose of
etonogestrel, had non-reproductive side effects without any increase in spermatogenic
suppression.
Conclusion: These data indicate the importance of the doses of progestogen and
testosterone for optimum spermatogenic suppression while minimizing side effects.
M016: A randomised controlled trial investigating the effects of gonadotrophin
withdrawal and progestogen administration on hormone production, metabolism and
action in the human testis. Thirty subjects were randomised to no treatment or
gonadotrophin suppression by GnRH antagonist with testosterone (CT) +/- additional
administration of the progestogen desogestrel (CTD) for 4 weeks before testicular biopsy.
Gene expression was quantified by PCR. Both treatment groups showed similar
suppression of gonadotrophins and sperm production and markedly reduced expression of
steroidogenic enzymes. Addition of progestogen resulted in expression of 5a-reductase
type 1 compared with both controls and the CT group. Inhibin-a and the spermatocytes
marker acrosin-binding protein were significantly lower in the CTD but not CT groups,
compared with controls, but did not differ between treated groups. Men who showed
greater falls in sperm production also showed reduced expression of these three genes but
not of the spermatid marker protamine 1.
ii
Conclusion: These data provide evidence for direct progestogenic effects on the testis and
highlight steroid 5a-reduction and disruption of spermiation as important components of
the testicular response to gonadotrophin withdrawal.
M017: Investigation of testicular function in normal men and those receiving a male
hormonal contraceptive regimen. 20 subjects were recruited and hourly blood samples
were taken over 24 hours for measurement of testosterone, inhibin B, LH, FSH and
Cortisol. Urinary excretion of testosterone and the testicular steroid epitestosterone was
also measured. In the controls, a diurnal variation in serum testosterone and LH but not
FSH was detected. The treated group had similar testosterone concentrations but showed
no diurnal variation. Periodicity was detected in inhibin B concentrations in 5 controls
and in 9 of the treated group. Urinary testosterone excretion did not show a diurnal
variation in either group, but this was apparent for epitestosterone with a morning peak in
both groups despite the markedly lower excretion in the treated men.
Conclusion: The diurnal variation of testosterone in normal men is due to change in
secretion rather than clearance and is largely LH driven. An endogenous rhythm in both
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The development of new commercially-viable male hormonal contraceptives has
been described for at least 20 years as being "5 years away". The mainstay of
development has largely been undertaken by the public sector, with the
pharmaceutical companies only participating in significant clinical trials in recent
years. However, they have now realised that these products would have commercial
viability and significant commercial trials of potential methods are now underway.
The background science requires a close understanding of the process and control of
spermatogenesis, regulation of testosterone secretion and its many functions, and the
influence on the human body of the administration of exogenous hormones. These
aspects will be discussed in detail in this introduction along with the previous work
in the field of male hormonal contraceptive development and a brief mention of
potential non-hormonal targets.
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Chapter 1.1: Physiology of Spermatogenesis
1.1A: Process of Spermatogenesis
Spermatogenesis is the process whereby immature germ cells undergo divisions,
differentiation and meiosis to become spermatozoa (see figure 1); this takes place in
the seminiferous tubules of the testis in close conjunction with the Sertoli cells, the
somatic cells of the seminiferous epithelium. The Sertoli cells are complex in
structure with numerous cytoplasmic processes encircling the developing germ cells.
They rest on the basement membrane and are responsible for the maintenance of the
blood-testis barrier [1], The developing germ cells are in intimate relationships with
the Sertoli cells and multiple genu cell types are associated with any one Sertoli cell.
The arrangements of the germ cells around Sertoli cells are not random; they are
arranged according to specific cellular associations [2], These are responsible for the
creating the cycle of the seminiferous epithelium, different arrangements of cellular
associations constituting a specific stage [3]. The different stages/phases of
spermatogenesis are highly ordered and occur over a specific length of time. In
different species varying numbers of recognizable cellular associations have been
identified within the testis, in the rat there are 14 but in the human there are 6 [4, 5].
Spermatogonia are the least differentiated germ cells in the testis and they are found
on the basement membrane between the Sertoli cells. They have been classified into
three subgroups: A spermatogonia, B spermatogonia and in some mammalian
species Intermediate spennatogonia have also been identified (not present in
humans). A new model of spermatogonial proliferation in the human testis has
recently been proposed with supporting data from non-human primates [6],
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Classically, the spermatogonial stem cells are believed to be a variant of the type A
spermatogonia [2]. The type A spermatogonia undergo a succession of mitoses to
become type B spermatogonia, which can be distinguished by their smaller nuclei
and the gathering of chromatin crusts around the nuclear membrane [5]. There are a
variable number of generations of both type A and type B spermatogonia depending
on the species in question. In a given species the numbers are fixed, for example in
man there are two type A and one type B [7], but in the monkey there are one/two
type A and four type B [5], The last mitosis of the type B spermatogonia forms pre-
leptotene spermatocytes, which have Sertoli cell cytoplasmic projections interposed
between themselves and the basement membrane. The pre-leptotene spermatocytes
are identified as being the generation at which the majority of DNA is synthesised
for the forthcoming meiotic stages [2], The synthesis of DNA ceases as the
spermatocytes enter the leptotene stage, identified by the presence of chromosomal
filaments, and then the homologous chromosomes pair off during the zygotene
phase. The ensuing pachytene stage, when the chromosomes thicken, is known as the
stage at which the spermatocytes are most vulnerable to damage [5], The swift
diplotene stage results in partial separation of the chromosome pairs, which is then
completed during the first meiotic division to become secondary spermatocytes
containing a single set of chromosomes. The second meiotic division follows, when
the secondary spermatocytes become the haploid round spermatids, which appear
very similar but with smaller nuclei. The whole cluster of spermatids is linked



























Figure 1: Spermatogenesis in the human male.
Molecular Biology of the Cell 4th Edition. Alberts et al.
Garland Science 2002, New York and London
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The final phase of spennatogenesis after meiosis is complete is known as
spermiogenesis, which comprises several distinct processes which transform the
spermatocytes into spermatozoa: formation of the acrosome and development of the
tail: condensation and reshaping of the nucleus; and removal of virtually all
cytoplasm. When all these processes are complete and all the characteristic features
of spermatozoa are present, it is released from the Sertoli cell into the seminiferous
tubule lumen [5]. The spermatozoa are then free to progress through the rete testis to
the ducts of the epididymis.
1.1B: Role ofGonadotrophins
The testis has the dual purposes of both honnone production and spermatogenesis,
dependent on the secretion of the pituitary gonadotrophins, follicle-stimulating
hormone (FSH) and luteinising hormone (LH) (see figure 2). The secretion of
gonadotrophins is under the control ofGnRH from the hypothalamus, with inhibitory
feedback via steroid and peptide hormones from the testis. The pituitary control of
spennatogenesis was first proposed in the 1920's by observing the effects of
hypophysectomy in the rat, followed by the reintroduction of pituitary extracts [9]. It
was later realised that two pituitary hormones were involved with differing effects on
Sertoli cells and on testosterone production [10], Luteinising hormone stimulates the
production of testosterone (T) from the Leydig cells of the testis while FSH acts on
receptors in the Sertoli cells. Therefore, suppression of these honnones should result
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Figure 2: Endocrine control of testosterone secretion with potential targets for
male hormonal contraception identified.
Image courtesy ofProfessor RA Anderson, University ofEdinburgh
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When gonadotrophins are withdrawn in the adult male sperm production ceases.
However, the interaction between the effects of the two gonadotrophins is poorly
understood. Gonadotrophin withdrawal may result from congenital GnRH
deficiency, GnRH analogue administration, spontaneous mutation in the GnRH
receptor, hypophysectomy, or suppression of gonadotrophins by exogenous
androgens in a contraceptive regime. The exact roles for testosterone and FSH in
spermatogenic regulation have also yet to be defined despite being extensively
investigated. It has been established that FSH is vital for normal development of the
fetal testis [11] but its role in the adult testis is less clear. Mice knockout models for
both the FSH receptor and the FSH-P subunit have been produced: both phenotypes
developed to sexual maturity and were fertile with qualitatively normal
spermatogenesis although their testicular size was significantly reduced [12-14], Men
with inactivating FSH receptor mutations demonstrate a similar picture with variable
reduction in sperm concentrations and reduced testes volumes but preserved fertility
[15, 16]. However, two individuals with inactivating FSH-P subunit mutations were
both azoospermic [17, 18], Experimental work in humans has demonstrated that
although the presence of FSH is not necessary for spermatogenesis to proceed, it is
important for quantitatively normal sperm production. Thus spermatogenesis is
maintained in men rendered FSH deficient due to hCG administration, and
administration of hCG to men on a high dose testosterone regime resulted in
restoration in spermatogenesis to 50% of baseline levels, but the addition of FSH
restored this to normal quantitative levels [19]. These data demonstrate that a
potential contraceptive regime aimed at reducing FSH secretion or action alone
would not be successful.
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Inactivating mutations of the human LH receptor affect male sexual differentiation
[20], but the range of effects is wide and dependent on the extent of receptor
inactivation. Testosterone production levels can be absent or variably low and the
phenotype extends from mild undervirilization to a complete lack of masculinization
[16]. A case report of a single male with total inactivation of the LH (3 subunit has
been described and he was phenotypically different to that seen with the LH receptor
mutation- being normally masculinized at birth but unable to progress through
puberty [21]. This observed difference is due to his responsiveness to intrauterine
hCG stimulating testicular testosterone secretion, as opposed to those subjects with
the LH receptor deficiency [20],
Activating mutations cause precocious puberty due to increased androgen production
during foetal life and the postnatal period, the degree of abnormalities seen depends
on the extent of the LH receptor mutation [22],
1.1C: Role of Testosterone
Testosterone (T) is produced by the interstitial Leydig cells of the testis.
Intratesticular concentrations of testosterone are generally 100 times that found in the
peripheral circulation. In humans they measure approximately 400-600ng/g versus
6ng/ml in serum [23, 24], The relationship between intratesticular testosterone
concentrations and spermatogenesis has been a subject ofmuch debate with the exact
concentration of testosterone required to support spermatogenesis being difficult to
quantify [25], In Leydig-cell depleted rats administered testosterone, it was possible
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for approximately 30% of normal testosterone concentrations to support
spermatogenesis [26] and no Leydig cell products other than testosterone appeared to
play a role in spermatogenic maintenance [27]. In a study on rats where FSH
secretion was supported, spermatogenic initiation and maintenance was achieved in
the presence of 10% of normal testosterone levels [28], The testicular androgen
receptor (AR) has been identified on Sertoli cells, peritubular cells and Leydig cells,
but not germ cells [29]; therefore it is assumed that the stimulatory effect of
testosterone acts on spermatogenesis via the Sertoli cell. Normal intratesticular
testosterone levels are far higher than that required to fully saturate the androgen
receptor, but when intratesticular levels are experimentally reduced in monkeys by
15-30% (still much higher than levels in the serum) significant impairment of
spermatogenesis results [30]. In gonadotrophin-suppressed humans administered
exogenous testosterone +/- progestogen a more profound suppression of
intratesticular T concentrations was seen with their intratesticular levels measuring
2% of that of controls. This reduction resulted in gross disruption of both
spermatogonial maturation and spermiation [31]. The reasons for the dependence of
spermatogenesis on supraphysiological levels of T are not clear; nor is there any
consistency between species of the degree of spermatogenic suppression achieved by
reducing the intratesticular T levels.
Testosterone is metabolised within the testis by type 1 or 2 isoenzymes of 5a-
reductase to dihydrotestosterone (DHT), a more potent androgen that has a higher
affinity for the androgen receptor [32, 33]. In locations with a high concentration of
T such as the testis, it is T that forms stable complexes with the AR [32]. However,
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in areas of lower T concentration and high 5a-reductase activity such as the prostate,
it is DHT that is the active androgen. In gonadotrophin-suppressed men receiving a
hormonal contraceptive regime of T +/- progestogen, despite the significant
intratesticular T suppression, DHT levels in the testis remained unaffected [31]. The
significance of this to male hormonal contraceptive development is as yet unclear,
but it may be that DHT levels may maintain some degree of spermatogenesis even if
intratesticular T levels are markedly affected. This theory is supported by data from a
contraceptive study investigating the DHT levels in men who received exogenous T
and became azoospermic or oligozoospermic. Serum and seminal plasma DHT levels
were higher in the men who did not achieve full spermatogenic suppression, which
implies a degree of up-regulation in oligozoospermia [34, 35], There is further
evidence of the role of 5a-reduced androgens in spermatogenesis from work in rats.
Adult male rats were given oestradiol and testosterone implants for nine weeks to
inhibit spermatogenesis. Subsequently they were administered increasing doses of
testosterone (implants of four different sizes 3, 6, 10 and 24cm) +/- a 5a-reductase
inhibitor, and hourly production rates of round spermatids were assessed using
stereological techniques. It was found that giving a 5a-reductase inhibitor
significantly suppressed the hourly round spermatid production at the two lower
testosterone doses. Therefore it seems that 5oc-reduced androgens do have a role in
restoration of spermatogenesis [36].
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1.1 D: Endocrine Control of Spermatogenesis
Spermatogenesis in humans and other species relies on the presence of both FSH and
T but their respective functions in this process are not well defined. Initiation of
some of the stages such as sperm release and germ cell survival require input from
both T and FSH [37-39], whereas some stages appear to be dependent upon
stimulation from only one. According to some studies in primates testosterone is
responsible for stimulating the production of a quantitatively normal number of type-
A spermatogonia [40], and FSH (with testosterone) for the creation of a normal
number of type-B spermatogonia. However, in other studies FSH also appeared
responsible for production of type-A spermatogonia [41, 42], FSH alone was
sufficient to reinitiate spermatogenesis in men during gonadotrophin suppression
induced by exogenous testosterone administration [43]. A complementary study
administering LH alone to men similarly suppressed also demonstrated a return to
pre-treatment spenn concentrations [44]. Both honnones are therefore able to
initiate and maintain nonnal spermatogenesis by acting via the Sertoli cell. These
findings suggest that testosterone and FSH act in a truly synergistic way via different
mechanisms, and are both equally important factors for nonnal spermatogenesis to
occur.
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Chapter 1.2: Testosterone Production and Metabolism
1.2A: Control of Testosterone Production
Testosterone is essential in the male for the development and maintenance of normal
reproductive tissues namely the testis, prostate, epididymis, seminal vesicles and
penis. It is also plays an important role in peripheral functions such as muscle
mass/strength, and hair growth. In order to maintain normal androgen levels in the
body the production rates of testosterone must be compatible with the rates of
excretion. Over 95% of testosterone is produced by the Leydig cells of the testis
which produce approximately 6-7 mg/day [45], the remainder of production is
contributed by the adrenal cortex. Testosterone is produced from cholesterol via the
A5 and A4 pathways, in humans the A5 pathway is the pre-dominant mechanism
with dehydroepiandrosterone (DHEA) as the first C19 intermediate (see figure 3)
[46]. The enzyme 3P-hydroxysteroid dehydrogenase (3PHSD) is responsible for the
essential step of converting A5-3P-hydroxysteroids to A4-3-ketosteroids and the
final stage in testosterone biosynthesis is the reduction of the 17-keto-group by 17p~
hydroxysteroid dehydrogenase (17PHSD) [22],
LH is the main hormone involved in regulation of Leydig cell number and function
and it exerts its action via the LH receptor [47], Human choriogonadotrophin (hCG)
can also activate this receptor because it has a very similar structure to LH. This
similarity has been exploited effectively in both basic science and clinical studies to
investigate the mechanisms of LH receptor stimulation. LH and hCG initially
produce a stimulatory effect on testosterone secretion this response is more
12
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Figure 3: Significant pathways in steroid production
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pronounced in rats than in man and manifests as a rapid rise in plasma T levels [48].
It is not currently clear why the response in man is not as marked [49].
Although LH is the dominant controlling force in T secretion other hormones have
been shown to have an effect on Leydig cells, namely thyroid hormone and the
glucocorticoids. Glucocorticoids have been demonstrated to have an inhibitory effect
on T production by interfering with steroidogenesis and inducing Leydig cell
apoptosis in rats [50], Thyroid honnone appears to have a contrary effect and has
been shown to both stimulate steroid production [51] and result in more rapid Leydig
cell differentiation [52].
Locally produced or paracrine factors have also been demonstrated to play a part in
the control of testosterone production. Over the years many differing studies have
identified factors including IGF-1, TGF[3, PDGF, Inhibin, interleukin, and TNFa
amongst others as having a role to play. In many publications both inhibitory and
stimulatory effects have been shown for these and other factors and the true degree to
which they contribute is hard to fathom as it is difficult to meaningfully assess them
all in isolation [48, 53, 54]. The extent of their contribution seems to be far
outweighed by the role that LH plays.
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1.2B: 24-Hour Testosterone Production
Serum testosterone levels in young healthy men are not constant throughout any
given 24-hour period. It is known that in young men testosterone exhibits diurnal
variation with maximal testosterone levels in the early hours of the morning and
minimal in the late afternoon/early evening [55]. This rhythmicity may remain in
very healthy older men, but can become blunted by the aging process and this
decline is accompanied by a decrease in mean serum T levels [56, 57]. When free T
or non-sex-hormone-binding globulin bound, (non-SHBG-T) is measured then the
differences between young and old men appear even more pronounced than when
only total- T is assessed [58], The cause for diurnal variation of serum T levels
remains unknown, it may be related to pineal gland melatonin secretion [59] or to
some as yet unidentified regulatory pathway possibly at testis level. There is
currently a high level of interest in the fall in mean serum testosterone levels seen in
the aging male, and much speculation as the existence of the "andropause." It is clear
that a reduction in testosterone levels progressively above the age of 55 is seen, and
this may contribute to many of the features ofmale aging including loss of body hair
and musculature. Currently, androgen replacement in elderly men remains a
contentious issue and should be reserved for those with T levels clearly below the
normal range for young men and unequivocal symptomatology.
The serum concentration of testosterone (T) is dependent upon a balance between
both T production rate (PR) and the metabolic clearance rate (MCR). Most of the
studies that have been undertaken in this field have been to establish normal T
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production rates, which it is possible to assess using a variety of methods, the
commonest being isotope dilution and mass spectrometry but testicular blood flow
studies and labelled T and urine collections have also been implemented. Reviewing
the data available, estimates ofT production rates in healthy young men have ranged
from 3.23mg/day to 7mg/day [60]. A study by Vierhapper et al in 1997 using isotope
dilution and mass spectrometry estimated T production rates to be 3.7 +/-2.2 mg/day
in healthy men aged 19-32 years [61]. This figure is lower than would be expected
from other data. An explanation for this may be that the high levels of labelled
exogenous testosterone used in this study partially suppressed endogenous
production. A recent similar study reported the 24-hour T production rate in young
Caucasian males as 9.11+/- 1.11 mg/day and the PR in middle-aged men was
significantly less at 3.88 +/- 0.27 mg/day [62]. Quantification of 24-hour T
production rates and serum T levels are highly relevant for male contraceptive
development as it is extremely important to avoid both supraphysiological and
subphysiological doses of testosterone if at all possible as they may have unwanted
effects.
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1.2C: Peripheral actions of Testosterone
a. Testosterone and Bone
Osteoblasts and osteoclasts are responsible respectively for production and
reabsorption of bone and an equilibrium between both these activities is essential to
maintain normal bone mass. Both androgens and oestrogens are necessary for
normal skeletal development and maintenance in men and women. The relative
importance of both of these sex steroids has been called into question more recently
in the male, with it now becoming apparent that oestrogen has a more significant role
to play than had been previously thought. It had long been assumed that androgens
played the dominant role in male bone physiology, with the evidence for this arising
from the fact that hypogonadism is associated with osteopenia/osteoporosis [63, 64]
and also from animal data [65, 66]. However, the conversion of testosterone to
estradiol by aromatisation is a crucial process, men with oestrogen receptor
mutations or a deficiency of aromatase demonstrate severe deficiencies in skeletal
development [67, 68], There is now known to be a correlation between endogenous
estradiol levels and both bone mineral density and bone loss [69-71], Bone density
is determined by peak bone mass achieved during development, and subsequent bone
resorption. Although both sex steroids are essential for the attainment of peak bone
mass the 25% higher bone density exhibited in men compared with women is
attributed to their higher testosterone levels [72]. In normal men bone density begins
a slow decline at the ages of 30-35 years, which has been attributed to a fall in
estradiol as opposed to testosterone [72].
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In hypogonadal men the effects of androgen replacement have been evaluated. In a
multicentre trial investigating the use of differing transdermal testosterone
preparations in 227 hypogonadal men, significant increases in hip and spinal bone
density were seen as assessed by dual-energy x-ray absorptiometry (DEXA) [73], A
study by Zitzmann et al in 2002 involving 521 men compared healthy controls with
both newly-diagnosed hypogonadal men and men receiving testosterone replacement
and monitored bone density by phalangeal quantitative ultrasound. They suggested
that the bone density of androgen-deficient men can be greatly improved by
testosterone replacement but may not reach that attained by healthy controls [74],
This outcome is supported by a similar smaller trial (n= 53) using DEXA for analysis
[75],
The potent synthetic androgen 7 a-methyl-19-nortestosterone (MENT) is resistant to
5a-reductase but is aromatisable. Therefore it should be prostate-sparing but still
support other androgen-dependent tissues. It has been tested as an androgen
replacement in 16 hypogonadal men and demonstrated evidence of prostate sparing
[76], But whilst sexual function and erythropoiesis were maintained, a reduction in
bone mass was seen over the 24 week treatment period in conjunction with a
reduction in serum markers of bone formation. It may well be that the MENT
metabolites are less effective in their activation of estrogen receptors than natural
estradiol [76],
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b. Testosterone and Skeletal muscle
Testosterone has a direct anabolic role to play in maintaining muscle size and
strength. It is known that healthy hypogonadal men have a lower fat-free mass and
higher fat mass when compared to age-matched eugonadal controls and that
administration of testosterone can significantly improve this situation [77-79], These
studies all demonstrated that physiological replacement of testosterone increased fat-
free mass, muscle size and strength. Similarly Mauras et al in 1998 reported that
causing experimental suppression of testosterone in healthy young men by
administration of a GnRH agonist resulted in an increase in fat mass, a significant
decrease in fat-free mass and a reduction in muscle protein synthesis [80].
A study by Bhasin et al in 2001 further examined this area in order to establish
whether these effects are dose-responsive. They enrolled 61 healthy eugonadal men
aged 18-35 years and assessed a broad range of androgen-dependent functions
including body composition, muscle size and strength, plasma lipids and
haemoglobin. All subjects received monthly GnRH agonist injections and were
randomised into one of 5 groups to receive weekly injections of 25, 50, 125, 300 or
600mg of testosterone enanthate for 20 weeks. They found that all the assessed
outcome measures above had a linear relationship to testosterone dose, but sexual
function and cognition did not vary significantly across the dose range. Therefore,
the anabolic function of GnRH treated healthy young men can be predicted by
testosterone dosage [81, 82], A further recent study by the same group has shown
that older men are just as responsive to the anabolic effects of graded testosterone
doses as their younger counterparts [83].
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But what are the effects of supraphysiological levels? For many years debate has
continued regarding the effects of exogenous testosterone on healthy individuals
resulting in supraphysiological levels; particularly with reference to abuse of
anabolic steroids by athletes and body-builders. In recent years improved imaging
techniques (magnetic resonance imaging and more refined body composition
analysis) have made smaller changes in muscle size and fat-free mass more
accurately detectable in order to establish how effective these compounds are.
Another investigation by Bhasin et al in 1996 focused on the effects of
supraphysiological doses on muscle strength and body composition. Forty-three
normal men were recruited and assigned to one of 4 groups: placebo and no exercise,
testosterone and no exercise, placebo plus exercise and testosterone plus exercise.
Subjects received either placebo or 600mg testosterone enanthate weekly for 10
weeks. Men in the exercise groups underwent standardised weight lifting training 3
times a week. Muscle size was assessed by MRI, and strength of the arms and legs
by bench presses and squat exercises. Men in the testosterone alone group
demonstrated a mean increase in triceps area of 13.2% +/- 3.3. The greatest overall
changes were seen in the T + exercise group with a mean increase in fat free mass of
9.5% (+/-1%) and increase in both triceps and quadriceps areas of 14% [84], A
study by Sinha-Hikim et al in 2002 investigated the mechanism behind the
testosterone-induced increase in muscle size: to establish whether it was due to
muscle hypertrophy or hyperplasia. Muscle biopsies were obtained from 39 men
before and after 20 weeks of treatment with GnRH agonist and different doses of
weekly testosterone enanthate (25, 50, 125, 300 or 600mg). The results demonstrated
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that testosterone-induced increases in muscle volume were due to muscle fibre
hypertrophy, rather than an increase in fibre numbers, and that the proportion of type
1 to 2 fibres remained unaltered. These changes were seen in a dose-dependent
manner with both the 300 and 600mg doses showing profound effect [85],
c. Testosterone and cardiovascular disease
After many years of research the relationship between testosterone and
cardiovascular disease is still not clear. In animal models in investigations of the
effects of testosterone on atherosclerosis results have proved conflicting. Studies of
castrated rabbits given androgen replacement alone or in conjunction with oestrogen
have shown either no change or a beneficial effect of testosterone on the size of diet-
induced atherosclerotic plaques in male animals, but a detrimental effect in female
rabbits [86-88], Adverse effects of testosterone administration were also seen in
female ovariectomised cynomologus monkeys [89], implying a sex specific effect of
exogenous testosterone on atherosclerosis.
From the animal models it may be inferred that low endogenous testosterone in men
and hyperandrogenism in women (e.g polycystic ovarian syndrome) are both states
more likely to promote the acceleration of atherosclerosis. This impression has not
however been confirmed by prospective studies [90, 91] but appears to be the true in
cross-sectional studies [92-94], Hypoandrogenism in men and the converse state in
women are known to be associated with obesity, insulin resistance, raised
triglycerides and LDL cholesterol, and lowered HDL cholesterol but the
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relationships cannot be straightforward as the correlation with atherosclerosis is
unproven [95-97].
In humans, knowledge of the effects of exogenous hormones is highly relevant for
both male contraceptive development and for testosterone replacement in the aging
male, and again the data is highly inconsistent. Exogenous androgens appear to have
a beneficial effect on some cardiac risk factors and on others a detrimental one. I will
take for examples the differences in effect on HDL-C and lipoprotein (a).
A low HDL-C level is seen as an important risk factor for cardiovascular disease
because HDL-C exhibits several actions that appear to be anti-atherogenic and
therefore a drug that may reduce atherosclerosis by raising HDL levels would
potentially have a significant impact [98]. In hypogonadal men testosterone
replacement has been demonstrated to mildly reduce HDL-C levels but have no
significant effect on total cholesterol, LDLs or triglycerides [77, 99]. In eugonadal
men administered exogenous supraphysiological doses of testosterone +/-
progesterone for male hormonal contraceptive trials have also demonstrated a
decrease in HDL-C [100-102]; further emphasising the importance of avoiding
supraphysiological doses.
Lipoprotein (a) levels vary greatly between individuals (0-300mg/dl), but it has been
seen in prospective population studies and case-control trials that a high Lp (a) is a
risk factor for cardiovascular disease [103, 104]. There is evidence that
administration of exogenous testosterone reduces Lp (a) levels and this may have a
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beneficial cardiac effect. Administration of supraphysiological doses of testosterone
enanthate has been found to decrease Lp (a) levels by up to 59% [105, 106], and men
whose own testosterone was suppressed by the GnRH antagonist cetrorelix exhibited
an elevation in Lp (a) levels by 40-60% [107], It is not possible to take the effect on
these risk factors in isolation, the effects must be considered as part of the complex
system of cardiovascular risk factors and the implications for the development of
male hormonal contraception are still unknown and may be further clarified when
large-scale hormonal contraceptive trials in men are undertaken.
d. Testosterone and erythropoiesis
The first studies demonstrating a relationship between testosterone and
erythropoiesis were reported in the 1940s when healthy rats were shown to develop a
significant increase in bone marrow activity and haemoglobin concentration when
administered testosterone [108], These findings were supported by a trial that
showed anaemia seen in orchidectomised rats could be reversed by testosterone
administration [109]. More recently trials showing that testosterone deficiency
causes anaemia in man have also reported [110, 111].
23
The effects of testosterone on erythropoiesis are mediated via a number of processes:
• Stimulation of erythropoietin (EPO)
• Stimulation of bone marrow erythroid colonies
• Increased iron incorporation in red blood cells
• Increased haemoglobin synthesis
• Enhanced red cell glycolysis
• Increased red blood cell 2,3-diphosphoglycerate levels [112]
These effects can be demonstrated in a number of clinical trials of androgen
replacement in hypogonadal men. Untreated hypogonadal men exhibit anaemia due
to low concentrations of both erythrocytes and haemoglobin, which can be improved
by androgen replacement therapy, a wide range of therapies have been investigated
in this regard. A study of 227 hypogonadal men who used transdermal testosterone
gel in two doses (100 or 50mg/day) showed significant rises in their blood cell mass
in a dose-dependent manner [79], The injectable preparation testosterone enanthate
(TE) was studied in 60 men rendered hypogonadal by administration of a GnRH
agonist where it was found to produce a dose-dependent response [81]. When the
effectiveness of TE was compared to that of the non-scrotal transdermal testosterone
patch in 66 hypogonadal men, both were found to significantly raise haematocrit but
the incidence of abnormally high elevations was higher in the TE group (43.8%) that
the patch users (15.4%) [113]. This is likely to be due to the wide fluctuation in
serum testosterone concentration seen with short acting injectable preparations such
as TE. The longer acting testosterone undecanoate (TU) results in a more stable
serum concentration and has also been investigated as a replacement T preparation in
24
hypogonadal men. It has been demonstrated to produce significant stimulation of
erythropoiesis but a lower incidence of polycythemia [114], Testosterone pellets are
the most long lasting form of testosterone replacement currently in use and they have
also been shown to produce a suitable rise in haematocrit in a dose-dependent
manner [115]. The synthetic androgen 7a-methyl-19-nortestosterone also
demonstrated an ability to support normal erythropoiesis when its efficacy as
androgen replacement was tested [76]. The maintenance of a normal haematocrit is
highly important in relation to both androgen replacement therapy and the
development of a marketable male hormonal contraceptive. Some men receiving
testosterone replacement do develop polycythemia [116, 117] and this has been
associated with an increased risk of cerebrovascular disease [118] although the
relationship with cardiovascular disease is not yet clear. It is important that any
delivery methods of testosterone used for both T replacement and a potential male
hormonal contraceptive maintain as steady serum T concentrations as possible.
e. Testosterone and the prostate
The prostate gland is androgen dependent and requires the presence of testosterone
for its growth and development at puberty, without it the gland will not grow to adult
size (approx 20 grams). Within the prostate gland testosterone is irreversibly
converted to 5a-dihydrotestosterone (DHT) by 5a-reductases, of which there are two
isoforms. Type 1 5a-reductase is only present in low levels in the prostate, but is the
pre-dominant form in the skin and liver [119]. The predominant isoform in the
prostate is type 2 5a-reductase and once converted by this DHT controls prostate
cellular proliferation via the androgen receptor. The intra-prostatic levels of DHT
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remain constant throughout a 24-hour period, thus avoiding the peaks and troughs of
testosterone in the circulation [55]. This constant hormone environment is critical to
maintain a balance of prostate growth and regression [ 120] and to control androgen
receptor function [121]. During exogenous hormone administration for male
hormonal contraceptive trials no significant change in prostate size has been
observed by transrectal ultrasound scanning [122] Although the question of: "how
does several years of exogenous androgen administration affect one's prostate cancer
risk?" currently remains unanswered and will stay so until long-term clinical trials or
indeed post-licencing assessments are made. The prostate cancer prevention trial
(PCPT) evaluated the effect of finasteride 5mg daily compared with placebo on the
incidence of development of prostate cancer. The trial was stopped early due to
premature attainment of the primary endpoint: a 25% reduction in the prevalence of
prostate cancer was observed in the finasteride treated group (prostate cancer
diagnosed in 18.4% of finasteride-treated subjects compared to 24.4% of placebo).
However, in the finasteride-treated group the detected prostate cancers showed more
aggressive Gleason grades [123], While this trial confirmed its primary hypothesis
that chronic suppression of intra-prostatic DHT reduces the incidence of prostate
cancer the implications of the secondary findings are less clear. Most evidence
points to the likely explanation of these findings as histological artefact because it is
known that histological assessment of the prostate is altered by finasteride treatment
[124, 125], With the recent arrival of the synthetic androgen 17a-methyl-19-
nortestosterone (MENT), which is resistant to 5a reductase, it is thought that it's
prostate-sparing action makes it an excellent candidate for a male hormonal
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contraceptive, with a probable reduction in safety concerns, and possible health
benefits if a chemoprevention effect on prostate cancer can be proven.
f. Testosterone and Behaviour
Sexual behaviour: The normal physiological range for testosterone in men is far
higher than that required to maintain normal sexual functioning, with the critical
level appearing to be around 3ng/ml [126], Studies of hypogonadal men and the
testosterone replacement therapy that they receive have produced a very convincing
case for the effect of testosterone on sexual arousal/desire and behaviour [127-129],
In male hormonal contraceptive trials administering supraphysiological doses of
testosterone, significant increases in arousal and desire have been reported but no
corresponding alteration in behaviour has been observed [130, 131]. There appears to
only be a beneficial effect on sexual behaviour when administering T to those men
with significantly low levels, i.e giving T replacement to eugonadal men with sexual
problems has not demonstrated any beneficial alteration in behaviour [132].
Aggression: There are data from many studies linking high endogenous T levels with
increased rates of aggressive behaviour. Many of these studies have been carried out
looking at the hormonal levels in violent male offenders, which is probably not
relevant to a target population for male honnonal contraception [133-135]. Looking
at the evidence from hypogonadal men taking exogenous testosterone replacement
and those men receiving testosterone as part of a male hormonal contraceptive trial it
is possible to gather data on the effects of exogenous T administration, and in both
these applications no effect on aggression has been observed [100, 129, 136, 137].
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Mood: The investigation of the role of testosterone in maintaining mood was
prompted by the observation that hypogonadal men given androgen replacement
reported a reduced incidence of low mood and emotional lability. In recent years,
further studies into this area have produced conflicting data with most studies failing
to show a link between endogenous T levels and depression [138, 139], but some
showing correlation between high endogenous T levels and emotional well-being
[140, 141], There is some strong data relating to the effects of administering
exogenous testosterone in elderly men with low/borderline T levels and in healthy
men without hypogonadism. In these groups a significant reduction in negative mood
scores and a significant improvement in sense of well-being were recorded on T
administration [138, 140], A recent study further assessing the effects of exogenous
testosterone administration in eugonadal men has reported detectable but minor
mood changes, however they concluded that in the dose range used for male
hormonal contraception these were unlikely to be significant [137].
Cognitive function: It is widely accepted that hormones play a significant role in sex-
specific cognitive abilities with women outperforming men at verbal skills, and
males excelling at non-verbal skills such as spatial awareness and mathematical
reasoning. The role of testosterone in spatial awareness in men has been confirmed
by studies on subjects with idiopathic or acquired hypogonadotrophic hypogonadism
[142, 143]. Men with life-long testosterone deficiency perform more poorly in these
tests than men with late-onset testosterone deficiency and normal controls. These
findings imply that the hormonal status during development has life-long
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implications for intellectual function. When healthy aging men were administered
testosterone to improve sexual function it was noted that they showed an improved
ability to complete a visual-spatial task compared to a placebo group [144],
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Chapter 1.3: Inhibin B
1.3A: Testicular Production
Inhibins are glycoproteins of gonadal origin that exert inhibitory effects on
gonadotrophin secretion. There are at least two biologically active forms Inhibin A
and B, these are heterodimers with each consisting of an a subunit and either Pa
(inhibin A) or pB (inhibin B). In women both inhibin A and B are important and are
produced by the granulosa and theca cells of the ovary. The physiologically relevant
form in men is inhibin B produced by the testis [145],
Inhibin subunits can be located in the testis from fetal life. By the second trimester
both a and pB subunits are expressed in Sertoli and Leydig cells, Pa can also be
isolated in Leydig cells and pB in developing gonocytes [146]. The pA subunit is
predominantly used for production of the homodimer activin A, hence inhibin A
synthesis remains low and is undetectable in the serum in the adult male [145, 147],
Following puberty the Sertoli cells continue to express only the a subunit and the pB
subunit is located predominantly in the germ cells and to a lesser extent in the Leydig
cells [148], Confirmation of this has been established by administering FSH to
healthy men [149], This does not lead to any significant increase in the circulating
levels of inhibin B however levels of pro-a C rise, suggesting that Sertoli cell
production of the a subunit is stimulated but that the release of the pB subunit
involves a more complicated process [150],
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1.3B: Control of Secretion
Inhibin B production is partly under gonadotrophin control. This has been
demonstrated by studies involving the administration of GnRH to men with
hypogonadotrophic hypogonadism [151, 152], Serum inhibin B concentrations were
seen to rise from approx 25-30% of normal into the normal range. Pre-treatment
inhibin B concentrations in these studies were highly variable and correlated with
testicular volume (Sertoli cell number). Men in these trials with higher pre-treatment
inhibin B concentrations were more likely to become fertile due to GnRH
administration.
Further evidence comes from male hormonal contraception trials. Men who were
treated with weekly exogenous testosterone injections (200mg testosterone enanthate
TE i.m) for up to 18 months. During the treatment phase FSH and LH became
rapidly suppressed and this trend was followed by significant spermatogenic
suppression and a fall in inhibin B levels to approx 30% of their pre-treatment values
[153]. A similar decline in inhibin B concentrations was reported in healthy men
receiving a combination of levonorgestrel and TE [147], So, it may be extrapolated
from these results that approx 70% of inhibin B is gonadotrophin-dependent.
However, suppression of inhibin B is not essential for effective gonadotrophic and
spermatogenic suppression in male hormonal contraceptive trials. No suppression of
inhibin B was seen in a trial using oral desogestrel and testosterone pellets [154], or
in a study of cyproterone acetate with TE [155] despite these trials reporting
significant spermatogenic suppression. The differences in degrees of inhibin B
suppression in these different contraceptive trials may reflect differences in the way
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that the various hormones used exert their effects i.e: they may act on different stages
of spermatogenesis. The 25-30% of Inhibin B that appears to be gonadotrophin-
independent remains present except in rare circumstances. Inhibin B can be totally
undetectable in patients with a significant testicular abnormality [145], or following
testicular irradiation [156]. In patients administered chemotherapy the fall in inhibin
B levels can be used to illustrate progressive testicular damage [157],
1.3C: Inhibin B and spermatogenesis
Inhibin B levels demonstrate a positive correlation with sperm concentration in the
ejaculate, this has been demonstrated in a variety of population groups from those in
the general population [158], men of known fertility [159] and also infertile men
[160]. The spermatids appear to have defined roles in the mechanism of inhibin B
secretion in the testis [150], Men proven to have Sertoli-cell only syndrome or
spermatogenic arrest at a pre-spermatid phase demonstrate levels of inhibin B that
are very low and may be undetectable. Whereas men with obstructive azoospermia
and spermatidic arrest exhibit normal Inhibin B concentrations [148, 161]. However,
it is also possible for a small minority of men with Sertoli-cell only syndrome to
produce some inhibin B, and the origin of that remains unknown [162]. Sertoli cells
also release inhibin B into the seminiferous tubules allowing for quantification of the
level present in seminal plasma. Seminal plasma inhibin B concentrations are can be
correlated to sperm count in fertile and infertile men and in men following
vasectomy and are significantly reduced in azoospermic men regardless of the cause
of their reduced sperm count [159, 163]. Confusingly, inhibin B can also be
undetectable in seminal fluid in some men with normal spermatogenesis and normal
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serum levels, and the reasons for this are not clear [164], In the previously mentioned
male contraceptive trial administering oral desogestrel with testosterone pellets,
spermatogenic suppression was not accompanied by a fall in serum inhibin B levels.
However, profound suppression of seminal inhibin B was seen [154].
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Chapter 1.4: Anti-Mullerian Hormone
1.4A: Role of AMH
Anti-Mullerian hormone (AMH) is a growth inhibitory glycoprotein related to
TGFps, inhibins, and activins [165], its existence was first proposed by the French
scientist Alfred Jost in the 1940s. Sertoli cells produce AMH in the fetal testis and
until puberty at high levels, then at low levels thereafter [166, 167], AMH is one of
the earliest Sertoli cell-specific proteins expressed by the gonad [168]. Serum AMH
levels therefore provide a useful marker of Sertoli cell maturation. As the blood-
testis barrier becomes established AMH secretion switches from the basal to the ad-
luminal compartment and therefore seminal-plasma levels rise above serum levels
[169, 170],
The main role of AMH is to induce Mullerian duct regression. However, as
production continues after this task has been performed, AMH must have further
functions. Roles proposed include control of germ cell differentiation [171, 172],
induction of the abdominal phase of testicular descent [173, 174], and suppression of
lung maturation [175, 176]. AMH acts via two known receptor types. The dominant
receptor is receptor type II which is present on cell membranes [177], This receptor
is responsible for ligand binding and then recruits receptor type I to transduce the
signal. The intercellular transduction pathways after receptor type I vary according to
the target cell [178], AMH is known to inhibit differentiation of precursors into
Leydig cells and expression of steroidogenic enzymes in primary Leydig cells [179]
and Leydig cell derived lines [180] via the type II receptor. Male mice with AMH
receptor II mutations exhibit Leydig cell hyperplasia [181]. There are three factors
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that influence Sertoli cell AMH production at puberty. The dominant controlling
factor is the rise in androgen levels but FSH production and the maturation of germ
cells also have a role to play.
1.4B: Regulation of AMH production.
Androgen regulation- the decrease in serum AMH levels commences at stage 2 to 3
of puberty [182] coincident with a rise in intratesticular T concentration, before a rise
in serum T levels is seen [183], Serum T rise and AMH fall is seen in normal puberty
and in both central and gonadotrophin independent precocious puberty. These
observations suggest that it is T as opposed to gonadotrophins that is responsible for
AMH down regulation [182], This is further supported by the fact that males in
which deficient androgen production is seen show abnormally high serum AMH
[184, 185]. The decline in serum AMH reflects iTT concentrations not serum T.
Males with hypogonadotrophic hypogonadism administered hCG develop a rise in
iTT levels and decrease in serum AMH. Conversely, those HH subjects receiving T
replacement directly are seen to have a rise in serum T levels predominantly and
therefore a less significant decrease in AMH production [186],
FSH regulation- Serum AMH is markedly decreased in FSH deficient prepubertal
mice, this correlates with reduced testicular volume and Sertoli cell number.
Administration of FSH to these animals results in a significant increase in AMH
levels [187]. In situations where the inhibitory effect of androgens is absent (such as
androgen insensitivity or androgen synthesis defects), and FSH is elevated, the serum
AMH recorded during puberty is often very high [184], The effects of FSH can be
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illustrated by a study involving patients with untreated congenital
hypogonadotrophic hypogonadism. These subjects were administered recombinant
FSH alone for one month and then in conjunction with hCG for a further two
months. AMH and inhibin B levels were seen to rise following FSH administration.
However, in contrast to the FSH alone, the combined FSH and hCG stimulation of
the testis induced a dramatic drop in AMH levels and a lesser but significant fall in
circulating inhibin B levels [188].
Germ cell regulation- AMH decrease and meiotic entry of germ cells are both
androgen-dependent processes. Experimental observations in XXsxrb male mice
demonstrate that meiotic genu cells have a role in the inhibition ofAMH expression.
XXsxrb mice are a natural model for XX males and are normally virilised [189].
They carry a translocated fragment of the Y chromosome containing the SRY gene
that induces testicular development leading to nonual androgen levels. As they carry
two XX genes and lack Y genes essential for spermatogenesis, the germ cells cannot
enter meiosis in these animals. In XXsxrb mice at puberty although a decline in
AMH expression is seen this is not as pronounced as in controls due to the lack of
meiotic cells [190].
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1.4C: Clinical Applications of AMH
AMH can readily be identified in the serum in infants, throughout childhood and
adults. In contrast to the high levels found in male infants, AMH is present at much
lower levels in females and does not become detectable until the second decade.
Therefore AMH provides a specific and sensitive marker for testicular tissue pre-
puberty. This makes it a useful tool for the evaluation of gonadal disorders such as
intersex states where it has been used to confirm the presence of testicular tissue
[191-193], It has also been used to confirm the complete removal of testicular tissue
postoperatively in patients undergoing orchidectomy for gender reassignment or
malignant potential. AMH has also been used as a tumour marker in some patients
with gonadal tumours such as AMH-secreting granulosa or sex-cord tumours [ 194,
195],
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Chapter 1.5: Current Male Hormonal Contraceptive Agents
1.5A: Introduction
Of the various solutions to the issue of the current lack of male contraceptives, the
hormonal approach is the nearest to commercial reality. There have been no new
male contraceptive methods developed in the last hundred years, with the currently
available methods of condoms and vasectomy changing little. Spennatogenesis is
dependent upon the secretion of the pituitary gonadotrophins, follicle-stimulating
hormone (FSH) and luteinising hormone (LH). The secretion of gonadotrophins is
under the control of gonadotrophin releasing hormone (GnRH) from the
hypothalamus, with inhibitory feedback via steroid and peptide hormones from the
testis. Luteinising hormone stimulates the production of testosterone from the Leydig
cells of the testis, which in conjunction with FSH acting on receptors in the Sertoli
cells stimulates spermatogenesis. Therefore, suppression of both of these hormones
is necessary to result in arrest of spermatogenesis, and this is basis of the hormonal
approach to male contraception. It has not so far been possible to suppress
spermatogenesis without also affecting testosterone secretion; therefore "add-back"
androgens have been an essential component of all trial regimes of male hormonal
contraceptives not based on administration of testosterone itself.
The development of this approach has been based in the public sector, with particular
support from the World Heath Organisation (WHO) and Contraceptive Research and
Development Program (CONRAD). A major barrier has been the lack of
development of new testosterone preparations with most men currently requiring
testosterone replacement receiving treatments that have not changed in decades.
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This is now changing, largely stimulated by the potential for large-scale androgen
replacement in ageing men, and several new preparations are emerging. This
contrasts with the wide range of progestogens available, in several formulations
including oral, long-acting injectables and implants. Although many studies
investigating this area have been perfonned in the last few years, there has been only
limited exploration of individual regimens, with little dose-response data and no
clear comparison of different progestogens. Despite this, there has been much
progress and it is now clear that effective hormonal male contraception can become a
reality with dialogue between industry and the regulatory authorities as to how a
novel medicine where drugs are taken by one person to have an effect on another
(i.e. prevention of pregnancy) can be developed.
Currently both androgen alone and androgen+adjunct regimes are under
investigation. The androgen only regimes consistently demonstrate a greater degree
of spermatogenic suppression in Asian as opposed to Caucasian populations [196].
The reasons for this are as yet unclear but may be related to a variety of factors
including ethnic differences in testosterone metabolism by 5a-reductase activity
[197], differences in hypothalamic/pituitary feedback sensitivity to testosterone, and
in rates of germ cell apoptosis [198], Androgen production rates vary between
Caucasian and Chinese populations and these appear to be environmental and dietary
related rather than predominantly genetic differences [199], Testosterone action via
the androgen receptor varies according to the number ofCAG repeats in the common
polyglutamine sequence on exon 1 of the gene encoding the androgen receptor,
resulting in varied transactivational activity. The number of CAG repeats is also
39
known to show ethnic variation [200], As well as known differences in the efficacy
of regimes between different ethnic populations there is also the problem of inter-
individual variation within a population in the degree of response to hormonal
methods. The reasons for this have yet to be fully defined, the degree of LH
suppression achieved can be indicative of the likely degree of spermatogenic
suppression, but there also appear to be gonadotrophin-independent mechanisms
involved [201], In recent years it has been accepted that although the gold-standard
of spermatogenic suppression to aim for is azoospermia, this degree of suppression
in not uniformly achieved and suppression to < 1 million/ml would provide an
effective method of contraception comparable with existing methods [202], The
addition of another substance to testosterone is important for improving efficacy,
particularly in Caucasian populations, and enables the dose of the testosterone to be
reduced, thus avoiding the potential problem of supraphysiological levels. Additional
agents may also accelerate the suppression of spermatogenesis and improve the level
of suppression achieved. The adjunct agents that have so far demonstrated greatest
potential are progesterone derivatives and GnRH antagonists.
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1.5B: Background
Although the principle of suppression of spermatogenesis by administration of
exogenous honnones was first established in the early 20lh century [203] it was the
landmark studies undertaken by the World Health Organisation in the 1980s and
early 90s that first truly raised the possibility of this theory developing practical
applicability. These two large multicentre studies proved that exogenous
administration of testosterone in the form of weekly intramuscular testosterone
enanthate (TE) injections (200mg) could result in both a significant rate of
azoospennia and acceptable contraceptive efficacy. The first study used the threshold
of azoospennia as the cut off to enter the efficacy phase and once subjects had
reached this level, attained by 70% ofmen (137 subjects), they used no other fonn of
contraception for a period of 12 months. This resulted in only one pregnancy [204],
The significant proportion of participants that failed to fully suppress
spermatogenesis led onto exploration of the contraceptive efficacy of
oligozoospermia. In a second study, subjects were allowed to enter the efficacy phase
in the subsequent trial once their sperm concentration had fallen below 3 x 106 /ml.
Inadequate suppression of spermatogenesis to preclude entry to the efficacy phase of
that trial occurred in only 2.2% of the 357 participants (8 subjects) while 268 men
became azoospermic (77%), a similar proportion to that demonstrated in the previous
study. There were no pregnancies demonstrated in the 230 person-years of
contraceptive exposure in the azoospennia group and four pregnancies occurred
during the 49.5 person-years of exposure in the oligozoospermia group. This data
results in an overall pregnancy rate of 1.4/ 100 person-years (C.I 0.4-3.7) [205, 206].
These studies demonstrated that honnonal suppression of spennatogenesis to levels
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sufficient for contraceptive efficacy was a possibility but the TE preparation used
was not without its drawbacks, particularly frequent administration by injection, a
significant proportion of men remaining inadequately suppressed, and the side
effects from the high dose of testosterone. While TE was not proposed as a potential




Testosterone preparations administered via a variety of routes are now available, but
not all of these have proved themselves to be both effective and acceptable as
potential male contraceptives. Testosterone is rapidly broken down by the liver in
first-pass metabolism and is therefore unsuitable to be administered orally. There is
only one orally active testosterone preparation- testosterone undecanoate and this has
a short duration of action, necessitating administration 8-hourly. This results in
extremely variable plasma concentrations [207], Despite this, oral TU has been
explored as a possible male hormonal contraceptive both alone and in combination
with oral cyproterone acetate (CPA) but the results were not encouraging due to the
frequency of drug administration, wide variation in plasma concentrations, and poor
suppression of spermatogenesis and gonadotrophins achieved [208, 209], Other oral
formulations, which result in absorption across the oral mucosa have been
investigated [210] but their development has not progressed. Recently a buccal
adhesive testosterone preparation has been developed and is now commercially
available, requiring 12 hourly administrations. This adheres to the gum surface and
slowly delivers testosterone directly into the systemic circulation thereby avoiding
first-pass metabolism. In studies involving hypogonadal men this preparation is well
tolerated and provides good androgen replacement [211, 212], but its potential as a
component of a male contraceptive is as yet unexplored.
Transdermal testosterone gels and patches would appear to be advantageous routes
of application to potential users. Unfortunately although appearing to be well
tolerated and effective for hormonal replacement in hypogonadal men [79, 213]
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patches have not fared well as experimental contraceptive agents either alone or in
combination with gestagens, demonstrating generally disappointing efficacy [214,
215]. It seems that the dose of testosterone released by the patches is not sufficient to
suppress spermatogenesis to the same degree seen with other delivery routes such as
long acting injectables or pellets as gonadotrophin suppression is incomplete. It is
also likely that the frequency of skin irritation seen with the patches may reduce
compliance. Testosterone gel is associated with far less skin irritation [79] but its
efficacy as a potential contraceptive agent has yet to be investigated. Both the buccal
and gel preparations appear to have significant advantages over the earlier self-
administered testosterone formulations. If this is translated into improved efficacy in
a contraceptive formulation with for example an oral gestagen, then the 'male pill',
or at least a comparable self-administered contraceptive, may become a reality.
a. Injectable Androgens
Testosterone enanthate (TE) administration results in effective spermatogenic
suppression but its short duration of action and therefore frequent administration
make it an impractical contraceptive agent. The duration of action of injectable
testosterone esters is related to the hydrophobicity of the side chain, and a range of
preparations have been developed. The most promising at present is a formulation of
TU, which has been developed by both European and Chinese pharmaceutical
companies. The Chinese formulation in tea seed oil maintained testosterone
concentrations in hypogonadal men above the lower normal limit for adult men for
50-60 days following a single administration of 500mg i.m [216, 217]. A subsequent
study investigating dose-finding in nonnal Chinese men as a potential contraceptive
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showed that 500mg every 4 weeks resulted in 11 out of 12 men becoming
azoospermic. All 12 men receiving the higher dose of 1000mg/4 weeks achieved
azoospermia but there was some accumulation of the testosterone [196]. A large
multi-centre contraceptive efficacy study investigating the same product in China
was reported last year. Volunteers initially received a loading dose of lOOOmg TU
i.m and then monthly maintenance of 500mg, only 9 of the 308 men recruited failed
to achieve azoospermia or severe oligozoospermia (< 3 x 106/ml) during the
suppression phase and 6 exhibited secondary failure causing sperm rebound and one
pregnancy. There were no pregnancies seen in the men who became adequately
suppressed, therefore the overall efficacy was 94.8% with no serious adverse effects
reported [218], In light of these favourable results a larger, 2 -year Phase III trial is
currently underway.
Trials in Caucasian men using the European formulation of TU in castor oil have
also been undertaken. This preparation has proved itself to provide adequate
androgen replacement in hypogonadal men [114] and has also come under
investigation as a male contraceptive both used alone and in combination with
gestagens [102]. When given as a 6-weekly injection in combination with daily oral
levonorgestrel it produced a comparable rate of spermatogenic suppression to that
achieved by weekly TE injections with two thirds of volunteers becoming
azoospermic [219]. This preparation will soon become commercially available.
Testosterone decanoate differs from TU by one carbon atom in the ester side chain.
There are no published data on its effectiveness as an androgen substitute in
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hypogonadal men but it has been investigated in healthy men as a contraceptive
agent given 400mg i.m every four weeks in combination with 2 etonogestrel
implants. 16 out of 20 subjects had become azoospermic by 12 weeks [220]. It
remains to be seen whether increasing the time period between injections of TD
would be possible, and further studies using this preparation are in progress.
b. Implantable Androgens
Pellets of fused crystalline testosterone have been available for many years for
androgen replacement in hypogonadal men. They are inserted into the anterior
abdominal wall using a trochar under local anaesthetic and completely dissolve.
They have almost complete bioavailability of testosterone and exhibit near zero-
order release resulting in very stable serum concentrations thus avoiding the peaks
and troughs associated with short-acting injectables [221], They have demonstrated
good acceptability and reproducibility in providing androgen replacement to
hypogonadal men with a dose of 4 x 200mg pellets lasting for approximately 5
months [222]. Studies investigating their contraceptive potential have shown that
using testosterone pellets on their own allows for a significant androgen dose
reduction whilst achieving the same degree of suppression of spermatogenesis and
gonadotrophins as exhibited by TE. Approximately 70% of subjects reached
azoospermia, but because the dose of androgen is lower the side effect prevalence is
lessened [223, 224], They do have the drawbacks of requiring minor surgery for their
insertion and there is a risk of extrusion, of approximately 5%.
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Testosterone pellets have also been used in combination with progestogens (see
below). In many of our own studies, we have administered the pellets in a regimen
of 400mg 12 weekly, ie approximately half the replacement dose for hypogonadal
men but administered twice as often, giving the same overall dose. While this results
in a fall in serum testosterone following initial administration, concentrations remain
within the normal range and are not associated with either symptoms or laboratory
evidence of hypogonadism. Importantly, this regimen avoids supraphysiological
testosterone concentrations, which are clearly associated with adverse effects and
may also enhance the depletion of testosterone within the testis. Testosterone pellets
remain the closest to an ideal method of administration for contraception because of
their pharmacokinetics: this is supported by the excellent rates of spermatogenic
suppression achieved. An improved formulation allowing easier administration
would be a major step forward in this field.
Synthetic androgens have in the past been associated with occasional liver damage
[225], However there is a resurgence of interest following from the establishment of
the potential for oestrogens with selective actions in different tissues, i.e. selective
oestrogen receptor modulators (SERMS). The androgen equivalents, selective
androgen receptor modulators (SARMS), are in development [226, 227], While not
a true SARM, the synthetic implantable androgen MENT (7a-methyl-19-
nortestosterone) shows some degree of tissue-specific action and has potential for
both androgen replacement and male contraception [228, 229]. MENT is 10 times
more potent at direct androgen-receptor mediated effects eg gonadotrophin
suppression than natural testosterone [230], but it is resistant to 5a-reductase. 5a-
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reductase normally acts as a testosterone amplifier by converting testosterone to the
more potent androgen dihydrotestosterone. Thus MENT will have relatively lower
potency in tissue in which testosterone is normally 5oc-reduced, such as the prostate.
MENT is however aromatised, which is of particular importance in the maintenance
of bone mass in men as in women. It should therefore provide advantageous
androgen replacement, being less stimulating to the prostate whilst maintaining other
androgen dependent tissues. In the context of contraception, this might confer non-
contraceptive health benefits. MENT acetate has been developed for use as a long
acting subdermal implant. It has been shown in this form to maintain sexual
functioning and mood in hypogonadal men [231] and to suppress gonadotrophins in
normal men in a dose-dependent manner [232], However over a 6-month period of
administration in hypogonadal men a dose of 2 implants which maintained other
androgen-dependent functions did not maintain lumbar spine bone mass [76], This
may reflect the importance of estrogens in maintaining bone mass in men. MENT is
a substrate for aromatase [233], but the low dose of MENT required for androgen
activity may result in too low a concentration of the aromatase product locally to
support normal bone metabolism. This has implications for the future development
of other synthetic androgens which are metabolised to estrogens in a different ratio to
natural testosterone. A study investigating the effectiveness of MENT acetate as a
contraceptive agent was recently reported. Thirty-five Caucasian men were recruited
and assigned to receive either 1,2 or 4 MENT acetate implants. Dose related
spermatogenic suppression was seen, with poor rates of suppression in the two lower
dose groups but 8 out of 12 men in the 4-implant group becoming azoospermia
Reversible raised haematocrit and haemoglobin concentrations and transient lipid
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changes associated with androgen administration were noted [234]. The value of




Testosterone only regimes for male contraception have had variable degrees of
experimental success, and on the whole have been found to result in a higher rate of
azoospermia in Chinese as opposed to Caucasian populations. Currently it is only the
long acting testosterone injectables and testosterone pellets that appear to be viable
contraceptive components and further work is needed to develop self-administered
forms of androgens that result in competitive rates of azoospermia. The use of
adjunctive agents such as progestogens and GnRH antagonists may result in higher




Desogestrel is a highly selective and potent progestogen that is converted by the liver
to the active metabolite etonogestrel [235], Desogestrel has been widely used as a
constituent of the combined oral contraceptive in women and is now available on its
own as Cerazette®. Etonogestrel is available as a subdermal implant (Implanon®)
[236] that releases approximately 50jig/day of etonogestrel initially and provides
contraception for three years in women [237], Both of these preparations have been
tested as experimental male hormonal contraceptives with encouraging results.
Desogestrel given in conjunction with TE resulted in good suppression of
spermatogenesis in two different studies. The dose combinations of 150pg/day
desogestrel and lOOmg TE i.m weekly [238], and 300pg/day desogestrel and 50mg
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TE i.m weekly induced azoospermia in all Caucasian subjects in their respective
groups (although n=8 only). Desogestrel (150pg or 300pg daily) has also been tested
in combination with testosterone pellets (400mg 12 weekly s.c) in Chinese and
Caucasian subjects. All subjects in the higher dose group became azoospermic
(n=28) as did 22/31 in the lower dose group [239], Similar results were obtained in a
study involving African men in Cape Town and Nigeria [240],
Etonogestrel implants combined with testosterone pellets may make a favourable
combination for long-acting contraception. Initial results were obtained in a study
that combined one or two Implanon implants with 400mg of testosterone pellets 12
weekly (n=28). In the higher dose group 13 out of 14 subjects achieved a sperm
concentration below 0.1 x 106 /ml and nine men in each group became azoospermic.
The pattern of spermatogenic suppression was less consistent in the one implant
group with 5 subjects developing a degree of partial recovery during the second half
of the treatment phase [241], The performance of this combination over a longer
treatment period is described in chapter two.
Levonorgestrel
The androgenic progestogen levonorgestrel (LNG) has been tested both in its oral
form and as an implant. Most results however have arisen from trials using it in
combination with TE [242]. In doses of 125pg/day in conjunction with lOOmg TE
weekly LNG was demonstrated to result in profound spermatogenic suppression.
This LNG dose showed reduced side effects ofweight gain and suppression of HDL-
C compared to higher dose groups (250 and 500pg) with no loss of spermatogenic
51
suppression [243] in Caucasian subjects. Implantable LNG has also been investigated
in combination with TE injections and transdennal testosterone patches.
Spermatogenic suppression in the patch group was disappointing with only 35%
achieving azoospermia versus 93% in the injection group (n= 20 and 14 respectively)
[244]. A trial of the combination of LNG implants in conjunction with long-acting
TU injections in China resulted in 6 out of 16 subjects becoming azoospermic but the
doses ofboth drugs used were probably suboptimal [245],
Depot medroxyprogesterone acetate
DMPA was initially trialled as a male contraceptive in conjunction with short acting
injectable TE and demonstrated encouraging rates of spennatogenic suppression in a
number of studies [246-248], Subsequently a single dose of 300mg DMPA with
800mg testosterone pellets was shown to be highly effective with 9 out of 10 men
becoming azoospermic [249]. The effectiveness of this combination was recently
confirmed in a contraceptive efficacy study administering 300mg DMPA every 3
months and 800mg testosterone pellets initially every 6 months, with this interval
later being reduced to 4 monthly. Spermatogenic suppression was excellent with 53
out of 55 Caucasian subjects suppressing down to below 1 x 106 /ml to enter the 12
month efficacy phase. There were no pregnancies reported in 35.5 person-years of
exposure and no serious adverse events, however the discontinuation rate was
disappointingly high (n=27) [250], DMPA has also been investigated in conjunction
with the long-acting injectable TU. In a study based in Indonesia where 500mg TU
in tea seed oil was given every 6 weeks in combination with 250 mg DMPA 12
weekly rapid and complete suppression of spermatogenesis was achieved [251]. In
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China a similar study randomised 30 men to receive lOOOmg of TU 8 weekly either
alone or with 150 mg/300mg DMPA also administered at 8 weekly intervals.
Consistent azoospermia or severe oligozoospermia was seen in all participants during
the 24-week treatment period, with the exception of two men in the TU alone group
who exhibited a rebound in sperm concentrations [252]
Norethisterone
NET was one of the first progestogens to be developed, it is reduced to 5a-NET and
aromatised to ethinyl estradiol. Because of low receptor affinity 5a-NET also
demonstrates anti-androgenic properties [253] in the prostate, therefore the overall
effects of NET are potentially complex. It is available both as an injectable depot
preparation, norethisterone enanthate (NETE), and as the oral product norethisterone
acetate (NETA). Early studies paired NETA with percutaneous testosterone gel and
produced encouraging results with all 5 Caucasian subjects becoming azoospennic
[254], The depot preparation NETE allows for long injection intervals similar to the
long-acting TU and it has now been investigated in combination with this androgen.
Subjects were administered lOOOmg TU and 200mg NETE 6-weekly and 13 out of
14 demonstrated azoospermia during the 24 week study [102], A follow-up study
also included a higher NETE dose group (400mg), a daily oral NETA group and an
initial testosterone-free interval of 2 weeks. There was no improvement in the high
levels of spermatogenic suppression achieved in the previous trial but an increase in
likely gestogen-related side effects such as nocturnal sweating [255]. This
combination currently offers the significant potential advantage of the two
components being administered in a single injection. As with other apparently
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highly effective combinations however larger studies are needed to establish more
accurately the true prevalence of azoospermia, i.e. whether a sufficiently large
proportion ofmen do not suppress to azoospennia to undermine its advantages.
Cyproterone Acetate
Cyproterone acetate is an orally active progestogen with antiandrogenic properties.
Initial studies in combination with TE injections showed favourable results with
good spermatogenic suppression [256, 257] but the antiandrogenic effects were
responsible for a decrease in haematocrit and haemoglobin and the short acting
injections are again impractical. It is likely that the antiandrogenic effect of CPA also
contributed to the highly effective spermatogenic suppression. Subsequently the
effects of CPA in conjunction with TU on Caucasian subjects have been evaluated.
In this study an initially higher dose of CPA (20mg/day) was given during the
suppression phase and then a lower maintenance dose (2mg/day) or TU alone
continued. There appeared to be no advantage is continuing CPA administration, as
the spermatogenic suppression was maintained just as well by the TU alone. This
study proposes a new potential role for the use of CPA during only the suppression
phase, thus avoiding the problems of long tenn administration [258],
New progestogens
The commonly investigated progestogens such as desogestrel, norethisterone, and
levonorgestrel often demonstrate unwanted effects such as weight gain and alter
serum lipoproteins during male contraceptive trials [239, 243, 255], There is
commercial interest in developing progestogens with limited androgenicity for
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female contraception but it is unclear whether these would have additional value in
the context of administration to men. One of the new progestogens developed is
dienogest, which has less antiandrogenic properties than CPA. It has suppressive
effect on gonadotrophins and testosterone in men but there are as yet no reported
contraceptive trials [259],
b. GnRH Analogues
GnRH agonists have established a wide range of roles in women's health, and in
some aspects of male health such as the treatment of prostate cancer. They have been
investigated both alone and in combination with androgen in potential contraceptive
regimens but disappointingly reduced the spermatogenic suppression achieved with
androgen alone [260, 261] and are therefore no longer considered as potential male
contraceptive agents. The mechanism for this is inadequately maintained
gonadotrophin suppression [262], GnRH antagonists, on the other hand, have shown
considerably more promise when used in conjunction with testosterone. In two early
studies using the prototype GnRH antagonist Nal-Glu in conjunction with TE,
azoospermia was achieved in 14 out of 16 participants [263, 264], Further
investigation ofGnRH antagonist preparations has been hampered by their high cost,
the need for frequent injections and the prevalence of histamine-like reactions. One
avenue for reducing these problems is their use only in the suppression phase of
treatment, with testosterone alone maintaining spermatogenic suppression thereafter
[265]. GnRH antagonists are becoming more widely available and are now part of
routine drug administration protocols in assisted conception. This generation of
antagonists has been demonstrated to show highly effective spermatogenic
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suppression in combination with an androgen [266]. New preparations with a longer
duration of action are becoming available: these include abarelix and tevarelix [267,
268] and acyline [269]. However, a recent study demonstrated no acceleration of
spermatogenic suppression or improvement in the rate of severe oligozoospermia by
the addition of acyline to a testosterone and progestogen regimen [270], Oral
nonpeptide GnRH antagonists are also being developed, and show good in vivo
suppression of the reproductive axis in non-human primates [271]. It is hoped that
these or similar new GnRH antagonists will be highly effective male contraceptive
agents but further data is needed.
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1.5E: Conclusion
A great deal of progress has been made in recent years towards a viable male
hormonal contraceptive but the ideal preparation is not yet clear (see table 1). Indeed,
it is likely that for maximum involvement ofmen a range of self-administered daily
regimens and long acting formulations will be required. Suppression to azoospermia
requires complete suppression of FSH and LH but is not achieved in all subjects with
many regimens thus far investigated. Current research efforts in this field consist of
many small studies resulting in fragmented data, with few consistent explorations of
combinations as highlighted by a recent Cochrane review [272], These studies are
also currently hampered by poor testosterone preparations but with the recent
development of new longer acting TU this situation may improve. Other new
preparations such as buccal testosterone and testosterone gel have yet to be
investigated as contraceptive agents. We have used testosterone pellets extensively in
our own contraceptive studies in combination with desogestrel and etonogestrel, as
discussed above. These studies and those of other investigators [201, 224, 250]
clearly show the advantages of a testosterone preparation with relatively stable
phannacokinetics thus avoiding the supraphysiological peaks present with even
longer acting injectable esters such as testosterone undecanoate and decanoate. This,
in addition to the dose-sparing achieved with these preparations, is likely to be the
basis for the high prevalence of azoospermia achieved in these studies and illustrates
the need for a preparation with the same phannacokinetics but improved
administration. Of the several progestogens under exploration only one currently has
the potential for a single combined product. An additional benefit is that
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progestogens appear to enhance spermatogenic suppression independent of the
degree of gonadotrophin suppression [201].
For the hormonal approach there is still concern regarding the lack of data available
on the long-term effects especially upon androgen dependent tissues such as the
prostate, and on lipid metabolism. These questions will need to be addressed by
larger, longer-term studies but the data described above clearly show that a viable
commercial product is a real possibility.
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Androgens Comment References
Testosterone Enanthate Previous data available for comparison,




Longer duration of action, but





Long acting with stable plasma concentrations
but require surgical insertion, and risk of
expulsion
Implant formulation at present. Possible health






Poor spermatogenic suppression, associated
with subphysiological testosterone
concentrations. Compliance may be an issue.
New self-administered preparations (gel, buccal
tablet) no yet investigated.
[214,215]
Levonorgestrel Androgenic progestin
Oral and implant preparations available
[242,-244]




Desogestrel Oral preparation. Potent and highly selective [238-240]
Etonogestrel Active metabolite of desogestrel, implant and
oral formulations. Implants give long duration
of action but readily reversible.
[220, 241,
273, 274]
DMPA Very effective but accumulation may present a
problem for dosing regimen
[247-250]









Expensive, require frequent administration.
Longer duration preparations becoming




Table 1. Products investigated as potential male hormonal contraceptives
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Chapter 1.6: Non Hormonal methods
There is a broad range of non-hormonal methods of contraception being developed
for men but few have yet to reach the clinical trial stage. The basis for this approach
is the identification of targets that are specific to the tissues involved in male fertility
ie within the testis, epididymis and vas deferens and the process of spermatogenesis.
The main potential advantage of this approach is that testicular hormone production
would be unaffected, avoiding many of the problems ofMHC, and there may also be
a more rapid onset of action. There presently seem to be more potential targets than
research groups able to investigate them.
However, further targets are currently being identified by the technique of
phenotype-driven mutagenesis. A large research programme is underway for the
identification and production of mutant mouse models of infertility in an unbiased
manner. The method of this programme is whole genome random mutagenesis with a
phenotype screen for breeding failure as the only phenotype [275]. Successful reports
from this programme could initiate investigation of completely new future
contraceptive targets. A brief introduction to some of the most promising targets
under current investigation is presented below.
1.6A: Testicular targets
Alkylated imino sugars are monosaccharide analogues that inhibit enzymes involved
in glycoconjugate biosynthesis and catabolism. These compounds have been
developed for the treatment of glycosphingolipid lysosomal storage diseases. One of
these compounds, NB-DNJ (N-butyldeoxynojirimycin), is now in clinical use for
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type 1 Gaucher disease. During preclinical studies it was noticed that male mice
became reversibly infertile following 3 weeks administration of this prototype drug
whereas female mice were unaffected [276]. The reproductive effects of NB-DNJ
and another agent NB-DGJ have been further investigated in male mice. Although
sperm morphology and physiology are altered the sperm remains genetically intact
[277] which is an important safety consideration. However, the positive findings in
mice have yet to be demonstrated in the human male. A recent study investigating
the agent miglustat in men found no effect on sperm concentration, motility and
morphology after six weeks of treatment [278],
1.6B: Immunocontraception
There is a large variety of potential targets in the male for immunocontraception,
including FSH and GnRH, sperm-specific antigens and epididymal proteins.
Immunisation against FSH in monkeys has not proved to be very encouraging,
demonstrating variable efficacy with some individuals becoming inconsistently
azoospermic and others having a sperm concentration that remained in the normal
range [279, 280],
A recent more promising study on non-human primates investigated the use of
immunisation against the protease Eppin as a non-hormonal contraceptive in the
male. Eppin is expressed only in the testis, epididymis and by sperm. Seven of nine
Bonnet monkeys immunised against Eppin demonstrated high antibody titres and all
of these seven monkeys failed to impregnate known fertile females. Sperm
production was not affected, the mechanism of action believed to be a specific
61
impairment of sperm motility. However, only five out of the seven monkeys regained
their fertility following cessation of immunisation, leading to concerns about the
reversibility of this approach to contraceptive development [281].
1.6C: Sperm Targets
A family of ion channel proteins unique to mature sperm have been identified,
known as CatSpers (cation channel of spenn). CatSper 1 initiates calcium influx into
the principal piece of the spenn tail, which is required for sperm motility [282]. Male
mice with significant mutations in the CatSper 1 gene are infertile but appear to be
otherwise normal [283], CatSper 2 appears to have a similar function and other
family members (CatSper 3 and 4) have been identified and are under further
investigation [284], A Catsper specific calcium channel blocker would have great
potential for an effective contraceptive agent.
1.6D: Vas Deferens targets
A variety of vas occlusives have been investigated with the hope of producing a
readily reversible male contraceptive. Traditional vasectomy is a highly effective
form of contraception but its reversibility is not intended or guaranteed, nor is that of
the slightly less invasive no-scalpel vasectomy technique. No-scalpel vasectomy is a
new adaptation that utilises a specially designed pointed forceps to effect skin
puncture and fix the vas. A number of biomedical devices have been developed in
the hope that they can provide a reversible method including wires, injectable plugs,
insertable plugs, a t-shaped control valve, and other intraluminal devices [285], One
of the most promising of these agents is RISUG, a co-polymer of styrene maleic
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anhydride (SMA) in a solvent vehicle of DMSO, which has undergone extensive
testing in man. While not preventing sperm production, it appears to destroy spenn
as they pass, causing 'necrozoospermia' rather than azoospermia. During a phase II
trial twenty-five men in India had this agent injected into the vas lumen bilaterally
and all showed the absence of viable sperm, in most within 2 months of
administration [286], Previous studies have confirmed non-toxicity in monkeys [287]
and reversibility has now been demonstrated in male rats [288] and also in primates
[289], A phase III clinical trial in man is currently ongoing [285]. The Intra-Vas
device (formerly known as the Shug), an insertable plug has also entered clinical
trials. A recent report from China compared the effectiveness of an intra-vas device
(IVD) with no-scalpel vasectomy (NSV). Although the IVD group had a slightly
reduced rate of contraceptive success (94.3% compared with 98.6% in the NSV
group at 12 months), they reported a higher level of patient satisfaction and a
reduced post-operative recovery time [290],
Conclusion
This is a brief description of a few of the large number of potential avenues for
development of non-hormonal contraceptives, but many of those described show
promise. There are distinct advantages to a non-hormonal method and it is to be
expected that further advances in this field will allow clinical trials to be undertaken.
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Chapter 2 Study M015: A randomised, single centre, open-label
study comparing the effects of MENT AC implants or testosterone
pellets in combination with etonogestrel implants on
spermatogenesis and androgen-dependent tissues in normal men.
2.1 Introduction
Male hormonal contraception is based upon regression of spermatogenesis following
suppression of gonadotrophins. The resulting profound reduction in testicular
testosterone production requires the administration of an androgen to prevent
hypogonadism, the androgen also effecting or contributing to gonadotrophin
suppression. Administration of testosterone alone provides effective reversible
contraception, as demonstrated in two studies which proved the validity of the
concept on which hormonal male contraception is based [204, 206]. However the
ideal of azoospermia was achieved in only 68% of Caucasian men and the dose of
testosterone was so large as to produce unwanted side effects including changes in
lipid metabolism, stimulation of the bone marrow, weight gain, and potential adverse
effects on the prostate gland. Administration of a progestogen or gonadotrophin
releasing hormone antagonist with testosterone has subsequently been demonstrated
in many studies to increase spermatogenic suppression while allowing a reduction in
the dose of testosterone towards that of physiological replacement [291, 292].
An alternative approach is the use of a synthetic androgen. Testosterone is a pro¬
hormone in many tissues, being converted by 5a-reductase to the more potent
androgen dihydrotestosterone (DHT) e.g. in the prostate or by aromatase to estradiol
e.g. in bone. A degree of tissue selectivity can thus be conferred by altered
susceptibility to conversion by these enzymes. This is exemplified by 7a-methyl-l 9-
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nortestosterone (MENT), a potent synthetic androgen that is resistant to 5a-reduction
but can be converted by aromatase to an active estrogen [233, 293]. Theoretically,
this will result in relative sparing of the prostate from androgenic stimulation while
maintaining other physiological androgen-dependent functions including sexual
behaviour, muscle and bone anabolism, and hypothalamic/pituitary feedback.
MENT may therefore have advantages over testosterone as androgen replacement
including as the androgenic component of a hormonal male contraceptive [229],
MENT implants (containing the acetate) induce dose-dependent suppression of the
hypothalamo-pituitary-testicular axis in normal men [232, 234] demonstrating
potential value in a male contraceptive regimen. Data to support the relative sparing
of the prostate by MENT have been obtained in non-human primates [294] and
hypogonadal men [76]. However while MENT maintains sexual behaviour and
haematopoiesis in hypogonadal men [231], it may be less effective at maintaining
bone mass [76],
MENT implants have recently been demonstrated to result in spermatogenic
suppression in normal men, with 8 out of 12 achieving azoospermia at a dose of 4
implants [234], There are no data on administration in combination with a
progestogen.
Progestogens investigated in this regard include levonorgestrel [219, 242],
cyproterone acetate [257, 258], medroxyprogesterone acetate [249, 250],
norethisterone enanthate [255, 295] and desogestrel [101, 154, 238] although there
are limited dose-relationship data and comparisons of different progestogens
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available [272]. Etonogestrel is the active metabolite of desogestrel and is formulated
as a long-acting implant for female contraception (Implanon®, N.V Organon, Oss,
The Netherlands). We have previously demonstrated that etonogestrel implants with
testosterone pellets result in dose-dependent suppression of spermatogenesis with
reduced non-reproductive effects such as alterations in lipoprotein metabolism and
weight gain [241, 273], The present study was designed to investigate the
effectiveness of MENT as the androgen component of a prototype male
contraceptive regimen including effects on non-reproductive tissues particularly the
prostate and bone, and compare it with a testosterone-based regimen. The
testosterone regimen was chosen to investigate whether an increase in the
testosterone dose with a sub-maximal etonogestrel dose would result in more
complete suppression of spermatogenesis and whether this would be associated with




Twenty-nine healthy Caucasian men with a mean age of 34.1 years (range = 23-50)
were recruited from the same general population as previous studies [239, 241, 273].
Inclusion criteria included good mental and physical health including no previous
history of depressive/aggressive disorders, body mass index (BMI) between 18-32
kg/m2, normal pre-treatment FSH, LH and testosterone concentrations and standard
biochemical and haematological parameters, and nonnal physical examination. Two
pre-treatment semen samples were required with sperm concentration >20xl06/ml
and motility and morphology within normal limits for the local population
(morphology >30% normal, motility >25% class A or >50% class A+B). All
participants provided written informed consent and were requested to continue their
current contraception throughout the study. The trial received ethical approval from
the Lothian Regional Ethics Committee and was performed according to GCP
standards.
Study design and medication
The study was a randomised, open-label trial investigating MENT implants or
testosterone pellets in combination with etonogestrel implants, both groups
scheduled for treatment for a 48 week period. Following two screening visits
subjects were randomised using sealed envelopes generated by a third party. The
MENT group were administered 2 implants each containing 135 mg MENT acetate
formulated as in previous studies to each release 400-500pg ofMENT/day [76, 234]
s.c with local anaesthesia into the medial aspect of one arm, and 2 etonogestrel
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implants 4cm long, each containing 68mg of etonogestrel, Implanon®, N.V
Organon) into the opposite upper arm. The testosterone group were administered 600
mg testosterone pellets (3x200mg, N.V Organon) s.c. with local anaesthesia into the
anterior abdominal wall repeated at weeks 12 , 24 and 36. This group also received 2
etonogestrel implants at the same time as first administration of testosterone. The
etonogestrel and MENT implants were removed at the end of the treatment period at
which time the subjects entered the recovery phase; the testosterone pellets dissolve
completely and do not require removal.
During treatment and recovery periods subjects were reviewed at 4-week intervals
for venesection and semen analysis, and assessment of adverse events or other health
issues. The number of episodes of sexual activity (sexual intercourse and
masturbation) over the preceding two weeks were recorded by interview at 12-week
intervals and at 16 weeks of the recovery phase at which times physical examination
was also performed, and testicular volume was determined using a Prader
orchidometer. Blood pressure was measured at every visit in the sitting position after
5 minutes rest using an automated device, and was required to remain < 140 mmHg
systolic or < 90 mmHg diastolic for the duration of the study. All subjects were
followed up until two semen samples had been submitted with sperm concentrations
above 20 xl06/ml.
Transrectal ultrasound using a biplanar probe (8 Mhz, Eccoccee, Toshiba, Stirling,
UK) was used to measure total prostate volume pre-treatment, at 24 and 48 weeks
treatment, and at 16 weeks recovery. Volume was calculated as 3.14/6 x AP
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measurement x Transverse measurement x Longitudinal measurement. Bone mineral
density at the lumbar spine and hip was determined at the same time points. All
recordings were made using the same instrument: QDR-4500A (Hologic Inc,
Bedford, MA) with standardization of the machine to correct for changes over time.
Assays
Blood samples were obtained at every visit, separated by centrifugation and serum
stored at -20°C until hormone assay. Testosterone, FSH, LH and estradiol by time-
resolved immunofluorometric assay (DELFIA, Wallac). Assay sensitivity was 0.3
nmol/1 for testosterone, 0.05IU/1 for FSH and LH and 50pmol/L for estradiol. The
intra-assay coefficients of variation (CVs) were <7%, inter-assay CVs were <5% for
FSH and LH <10% for testosterone and estradiol. Inhibin B was assayed as
previously described [159, 296] with an assay sensitivity of 7.8pg/ml. MENT in
serum and that remaining in the implants following removal was measured by
radioimmunoassay as described previously [297, 298] with intra-assay CV was 3.8-
7.9% and the inter-assay CV was 8.0-12.3%. Due to cross-reactivity with
testosterone and other serum factors in the MENT assay a mean value of 0.39 ± 0.01
nmol/1 is seen in the samples prior to MENT treatment. Samples were analysed for
biochemical and haematological parameters (including cholesterol and HDL-C) by
autoanalyser at 12 weekly intervals.
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Semen Analysis
Semen samples were submitted following 3-7 days abstinence. World Health
Organisation methodology was used to assess sperm concentration at all assessments
[299]. Azoospermia was confirmed by thorough examination of the re-suspended
pellet following centrifugation at 3660g for 15 minutes.
Data Analysis
All results are presented as mean ± SEM. Serum hormone and biochemical data were
log transformed before analysis by ANOVA for repeated measurements, and sperm
concentrations were cube root transformed before ANOVA with Tukey's post hoc
test. Proportions of men achieving thresholds for spermatogenic suppression to
azoospermia and <lxl06/ml were analysed by Fisher's exact test. For all
comparisons, a P of <0.05 was considered significant. Sexual activity data was
analysed by non-parametric testing
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2.3 Results
Subjects, adverse events and withdrawals
29 subjects were recruited and randomly assigned to the two treatment groups. An
additional 14 men were excluded during screening and 8 failed to complete the
screening process. There were no significant differences in pre-treatment variables
between the two groups (tablel). Three subjects in the MENT group chose to leave
the study after 8 weeks of treatment, two because of symptoms of low libido and
erectile dysfunction and one for personal reasons unrelated to the study. Two
subjects in the testosterone group withdrew after 24 weeks of treatment, one for
personal reasons and the other for symptoms of labile mood, sleep disturbance and
nocturia. Adverse events experienced included reduced libido and erectile function in
4 additional subjects in the MENT group who completed treatment. In the
testosterone group, single pellets were extruded in 2 subjects: both occurred one
week prior to scheduled re-administration and were therefore not replaced. One
subject in the testosterone group reported increased libido and acne.
Due to the high incidence of reports of low libido and early withdrawal from the
study in the MENT group it was decided in consultation with the study Data
Monitoring and Safety Committee to shorten the MENT treatment period to 24
weeks whereas men in the testosterone group completed 48 weeks treatment.
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Table 1. Pre-treatment values for all subjects, mean ± SEM. MENT group n=13,
testosterone group n=16.
MENT and Testosterone concentrations
Serum MENT concentrations in that group demonstrated an initial peak at four
weeks of 1.1 nM ± 0.1 nmol/L followed by a gradual decline to 0.54 ± 0.05 nmol/L
by week 24 (figure la). Analysis ofMENT remaining in the implants after removal
demonstrated that the implants had released 31 ± 2% of original MENT content over
24 weeks, giving a calculated average release rate of 117 ± 6pg/day/implant.
Implants removed after shorter insertion periods (51 -60 days, n=3) showed a higher
calculated release rate at 329 ± 6pg/day/implant. The two men who withdrew from
the study because of reduced libido had similar serum MENT concentrations to the
rest of the group, as did the other 4 who had reduced libido but continued.
Testosterone concentrations in this group fell rapidly to 2.0 ± 0.4 nmol/L at 4 weeks
(P<0.0001 vs. pre-treatment, figure lb), and remained very low for the duration of
treatment with no significant changes from values at 4 weeks.. Following removal of




Weeks of treatment recovery
(a)
Weeks of treatment recovery
(b)
Figure 1: Serum concentrations of (a) MENT, (b) testosterone during treatment and recovery
phases. MENT group (square symbols) n=13, testosterone group (round symbols) n=19,
mean ± sem. The MENT group received drug treatment for 24 weeks, the testosterone group
for 48 weeks. Testosterone was administered at weeks 0, 12, 24 and 36. In (b) the normal
range is indicated by the broken lines.
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Serum testosterone concentrations in the testosterone group were significantly
greater than in the MENT group at all time points during treatment (P<0.0001, figure
lb). There was some fluctuation in keeping with the schedule of testosterone
administration at 12-week intervals with troughs prior to re-administration and peaks
4 weeks later. Trough and peak concentrations rose during the study, indicating some
accumulation. After an initial fall over the initial 12 weeks of treatment (P<0.001)
testosterone concentrations were similar to pre-treatment at 24 weeks but at 28 and
40 weeks were significantly higher than pre-treatment (both P<0.001). However
average testosterone concentrations over both the first and second 24 week periods
were not significantly different to pre-treatment (22.6 ± 1.9 vs. 20.2 ± 1.4 vs. 26.9 ±
1.5 nmol/L pre-treatment, 4-24 weeks and 28-48 weeks respectively).
Sperm concentrations
Both groups showed profound suppression of spermatogenesis during the initial
months of the study. At 12 weeks of treatment 8 of 10 subjects (80%) in the MENT
group and 13 of 16 (81%) in the testosterone group demonstrated spermatogenic
suppression to <lxl06/ml with 3 and 11 subjects respectively being azoospermia
However spermatogenic suppression with continuing treatment was inconsistent in
the MENT group (figure 2a). Only 4 men maintained suppression at <lxl06/ml until
24 weeks whereas partial recovery was seen in the remaining 6. In the 2 men who
did not achieve suppression to <lxl06/ml sperm concentrations were >20xl06/ml at
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Figure 2: (a) Sperm concentrations during treatment phases expressed as % of group achieving
significant levels of spermatogenic suppression (>3xl06/ml,<3xl06/ml,<lxl06/ml and azoospermia),
shown as (1) MENT group and (2) T group, (b) Sperm concentrations during treatment and recovery
phases. MENT group (square symbols) n=13, testosterone group (round symbols) n=19, mean ± sem.
The MENT group received drug treatment for 24 weeks, the testosterone group for 48 weeks.
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In contrast the testosterone group continued to demonstrate profound and maintained
suppression of spermatogenesis (figure 2a). At 24 weeks of treatment 14 out of 16
subjects (88%) were azoospermic, and by the end of the treatment period all subjects
demonstrated azoospennia (n=14). One of the two men not azoospermic at 24 weeks
withdrew from the study for personal reasons unrelated to the study, and the other
became azoospermic at week 44 of treatment. The range of time to achieve
azoospermia was therefore 4-44 weeks, with a median time of 12 weeks. Once men
in the testosterone group had become azoospermic, none showed significant
resumption of spermatogenesis during treatment: spermatozoa were detected only in
the centrifuged pellet of the ejaculate in one individual on one occasion.
Recovery was rapid following implant removal in the MENT group with 9 out of 10
subjects achieving sperm concentration >20xl06/ml within 16 weeks of follow-up.
Slower recovery was seen in the testosterone group, with a median duration of 28
weeks (figure 2b). One subject continued to show sperm concentrations of 10-
15xl06/ml after over 1 year of follow-up, with normal total sperm number, sperm
motility and morphology, and gonadotropin concentrations. His mean pre-treatment
sperm concentration was 31xl06/ml. A second subject underwent vasectomy before
his spenn concentration had recovered to >20xl06/ml, 64 weeks after removal of
etonogestrel implants.
Other reproductive hormones
Initial suppression of both FSH and LH was rapid and profound in both treatment
groups (figure 3). In the MENT group mean FSH was 0.18 ± 0.03 IU/1 after
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Weeks of treatment
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Figure 3: Serum concentrations of FSH and LH during treatment and recovery
phases. MENT group (square symbols) n=13, testosterone group (round
symbols) n=19, mean ± sem .
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four weeks of treatment. However, progressive partial escape from suppression was
evident with a rise to 1.29 ± 0.21 IU/1 at 24 weeks (P=0.04, ANOVA of treatment
values). Concentrations were similar to pre-treatment in the recovery phase. In the
testosterone group the initial profound suppression was well maintained throughout
the treatment period (0.43 ±0.13 IU/1 at week 24 and 0.59 ± 0.24 IU/1 at week 48,
figure 3). Minor rises were seen at times of trough testosterone concentrations that
did not reach statistical significance. In the recovery phase there was an overshoot to
above pre-treatment concentrations (6.6 ±1.1 IU/1 at 16 weeks post-treatment vs 3.7
± 0.5 IU/1 pre-treatment, P<0.01).
LH was profoundly suppressed in both treatment groups over the initial 12 weeks of
treatment (figure 3). In the MENT group there was a small rise during continuing
treatment but this did not reach statistical significance (0.23 ± 0.09 IU/L at 12 weeks,
0.57 ±0.13 at 24 weeks, figure 1). In the testosterone group the suppression was
more complete and consistent for the duration of treatment (0.12 ± 0.05 IU/L at 24
weeks; 0.16 ± 0.12 at 48 weeks).
Estradiol concentrations demonstrated a marked fall in the MENT group at 12 and 24
weeks treatment (P<0.001, figure 4a). In the testosterone group the results paralleled
the testosterone concentrations with a small fall seen at 12 weeks (P<0.001),
recovering by 24 weeks (ns vs pre-treatment, P<0.01 vs 12 weeks). There was a
significant difference in estradiol concentrations (P=0.01) between the two groups at
24 weeks.
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Screening Wk 12 Wk 24 Wk 36 Wk 48 Wk 16 F/Up
Weeks of treatment Recovery
(b)
Figure 4: Serum concentrations of (a) estradiol and (b) Inhibin B during treatment and
recovery phases. MENT group (square symbols) n=13, testosterone group (round
symbols) n=19, mean ± sem .
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Inhibin B concentrations showed a significant decline during treatment in both
groups, but differed between groups (P=0.01, figure 4b). In the testosterone group,
inhibin B concentrations declined during the first 24 weeks of treatment, with little
fall thereafter. There was however a significant further fall during the recovery
phase (P<0.0001 vs week 48), with a nadir at 12 weeks recovery. There was an
inverse relation between inhibin B and FSH during the recovery phase (P=0.004 at
16 weeks). In the MENT group, inhibin B concentrations were only significantly
lower than pre-treatment at 8 weeks (P=0.001).
Haematology and Lipids
Haemoglobin concentrations were significantly increased in the MENT group at 12
weeks but this did not persist at 24 weeks (table 2). A similar pattern was also seen in
haematocrit but this did not reach statistical significance. In the testosterone group a
slower progressive rise in haemoglobin concentration (P=0.0006) was observed
which only became significantly greater than pre-treatment at 48 weeks, and returned
to pre-treatment values during the recovery period. There was also a significant
overall rise in haematocrit (P=0.009) in the testosterone group although none of the
individual treatment time points were significantly different from pre-treatment
(table 2).
There were significant falls in HDL-C concentrations in both groups during
treatment with return to pre-treatment values in the recovery period (table 2). In both
groups HDL-C was significantly lower than pre-treatment at all time points during
80
the treatment phase. Cholesterol concentrations in the MENT group but not the
testosterone group also showed a gradual fall during treatment at 24 but not 12
weeks, returning to pre-treatment concentrations during recovery (table 2). There
were no significant changes in triglyceride or LDL-C concentrations in either group.
Neither group demonstrated any significant changes in any biochemical variables
throughout the study.
Pre- 12 weeks 24 weeks 36 weeks 48 weeks Recovery
treatment
Haemoglobin (g/1)
T Group 152 +2.5 149 ±2.2 153 ±2.1 154 ±2.5 157 ± 154 ±2.5
MENT Group 149 ±2.9 154 ±3.3* 148 ±2.4 - 2.5** 148 ±2.0
Haematocrit
T Group 0.45 ±0.01 0.4 ±0.01 0.4 ±0.01 0.46 ±0.01 0.46 ± 0.4 ±0.01
MENT Group 0.44 ±0.01 0.4 ±0.01 0.4 ±0.01 - 0.01 0.43±0.01
HDL-C (nmol/1)
T Group 1.4 ±0.1 1.2 ±0.1* 1.2±0.1** 1.2 ± 1.1 ± 1.3 ±0.1
MENT Group 1.4 ±0.1 1.2±0.2** 1.2+0.1** 0.01** 0.1** 1.3 ±0.1
Cholesterol (nmol/1)
T Group 4.8 ±0.2 4.4 ± 0.2 4.6 ± 0.2 4.5 ±0.2 4.7 ± 0.2 5.0 ±0.2
MENT Group 4.9 ±0.2 4.6 ± 0.2 4.4 ± 0.2* - - 4.9 ±0.2
LDL-C (nmol/1)
T Group 2.8 ±0.2 2.6 ±0.2 2.9 ±0.2 2.9 ±0.2 3.0 ±0.2 3.1 ±0.2
MENT Group 2.9 ±0.2 2.9 ±0.2 2.5 ±0.2 - - 2.9 ±0.2
Triglycerides
(nmol/1) 1.3 ±0.2 1.4 ±0.2 1.3 ±0.3 1.1 ±0.1 1.5 ±0.2 1.4 ±0.2
T Group 1.5 ±0.2 1.3 ±0.2 1.7 ±0.2 - - 1.5 ±0.2
MENT Group
Table 2. Serum values of haematology, lipid and PSA results as mean ± sem. MENT
group n=13, testosterone group n=16. * p<0.05, ** P<0.01 vs pre-treatment
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Figure 5: Systolic and diastolic blood pressure during treatment and recovery phases.
MENT group (square symbols) n=13, testosterone group (round symbols) n=19, mean ±




A significant rise in systolic blood pressure was observed in the MENT group
throughout the treatment period (P=0.02, figure 5) with no significant change in
diastolic blood pressure. Systolic blood pressure was not significantly different to
pre-treatment during the recovery phase. There were no significant changes
observed in the testosterone group in either systolic or diastolic blood pressure
during the treatment period.
Testes and Prostate
Both treatment groups showed decreases in testicular volume during the study
period. This fall was only transient in the MENT group, falling to 71% of pre-
treatment volume after 12 weeks of treatment (p<0.01) but was not significantly
different to pre-treatment at 24 weeks. In the testosterone group mean testis volume
decreased significantly by week 12 (p<0.01) falling to a nadir of 67% at 48 weeks
(p<0.001).
There was no significant change in prostate volume over the course of the study in
the MENT group (table 3). However, in the testosterone group a significant increase
in prostate volume was seen at the end of the treatment period (P=0.007) and it
remained slightly elevated after 16 weeks in the recovery phase (P<0.05 vs pre-
treatment, not significant vs week 48). Serum prostate specific antigen (PSA)
concentration demonstrated a significant fall in the MENT group (table 3) at both 12
and 24 weeks of treatment but was unchanged in the testosterone group.
83
Body Composition, Sexual Behaviour and Bone Mineral Density.
There was no change in weight in the MENT group, but an increase in the
testosterone group by the end of the treatment period (P=0.02), which persisted into
the recovery period (table 3). There were no significant differences in sexual activity
in either the MENT or testosterone treatment groups (table 3). Bone mineral density
remained unchanged in both groups at both hip and spine throughout the treatment
period (table 3).
Pre- 12 weeks 24 weeks 36 weeks 48 weeks Recovery
Treatment
Weight (kgs)
T Group 80.8 + 3.8 80.6 ±3.4 82.2 ±3.5 83.6 ±4.1 84.2 ±3.9* 84.1 ±3.8
MENT Group 80.5 ±3.0 83.0 ±3.6 81.5 ±3.7 - - 81.3 ±3.3
Prostate vol
(ml) 14.7 ±1.3 - 16.2 ±0.9 - 17.4±0.9** 16.9 ±1.2
T Group 16.3 ±1.4 - 15.8 ±2.3 - - 16.4 ±1.4
MENT Group
PSA (ng/ml)
T Group 0.8 ±0.1 0.87+0.1 0.84 ±0.1 0.73 ±0.1 0.72 ±0.1 0.68 ±0.1
MENT Group 1.1 ±0.2 0.77 ± 0.74±0.1** - - 0.80 ±0.1
0.1 **
Testis vol (ml)
T Group 18.6 ±0.9 13.7±0.9** 12.4±0.6** 12.6±1.2** 11.5±1.1** 19.0 ±0.9
MENT Group 18.1 ±0.9 12.9 ± 15.4 ±1.1 - - 18.6 ±1.1
1.0* *
Sexual activity
T Group 7.1 ±0.9 8.7 ±1.5 7.8±0.9 7.6 ±1.8 7.4 ±1.9 7.1 ±1.2
MENT Group 6.9 ±0.9 5.9 ±1.3 6.4 ±1.3 - - 7.9 ±2.1
Spine BMD
(g/m2) 1.03 ±0.02 - 1.03 ±0.03 - 1.08 ±0.02 1.01+
T Group 1.05 ±0.04 - 1.04 ±0.04 - - 0.06
MENT Group 1.01±
0.04
Total Hip BMD 1.08 ±0.02 - 1.08 ±0.02 " 1.10 ±0.03









It is now established that administration of sex steroids can suppress
spermatogenesis sufficiently and reversibly to allow development as a hormonal
contraceptive for men [291, 292, 300]. What is less clear is how to optimise the rate,
extent and inter-individual consistency of spermatogenic suppression while
minimising the potentially adverse non-reproductive effects of treatment, which
largely reflect administration of supraphysiological doses of testosterone.
Administration of a progestogen allows considerable dose-sparing of testosterone,
and previous studies using long-duration formulations of both testosterone and
progestogens suggest that this approach may also allows a reduction in dose while
maintaining efficacy [241, 249, 273].
The synthetic androgen MENT may offer advantages over testosterone for
replacement therapy both in hypogonadal men and as a component of a hormonal
male contraceptive [231, 234]. The potency may allow alternative formulations with
an increased dosage interval, and the restricted metabolism may provide relative
sparing to the prostate [293], For application in male contraception, efficacy in
gonadotrophin and spermatogenic suppression are essential and have been
demonstrated by MENT implants alone [232, 234], However as with testosterone
alone, the dose of MENT required for adequate suppression was associated with
undesirable non-reproductive effects indicating supraphysiological androgen action,
i.e. increases in hemoglobin and hematocrit,. Administration with a progestogen
allows a lowering of the dose of androgen towards physiological replacement. We
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have previously demonstrated that two MENT implants formulated as in the present
study appeared to provide replacement in hypogonadal men for 24 weeks [76].
Similarly, the dose of etonogestrel used here when combined with testosterone
resulted in marked but not maximal suppression of spermatogenesis [241], We
therefore investigated this dose of etonogestrel with MENT in comparison with
testosterone.
There was rapid spermatogenic suppression during the initial 12 weeks of treatment
in both groups, with approximately 80% of both groups achieving suppression to <1
xl05/ml at that time. This is comparable to the most effective regimens previously
reported [255, 301] indicating the potential value of MENT in male contraception.
Thereafter however suppression in the MENT group was inconsistent and some
subjects complained of reduced interest in sex. Subsequent measurement of serum
MENT showed similar concentrations to those previously reported using this
formulation [76] although the assay has a high background for measurements in
serum reducing its accuracy. Determination ofMENT remaining in the implant after
removal at the end of the study demonstrated that the release rate was low, although
in those men in whom the implants were removed early the initial release rate was as
expected. It therefore appears that a greater sustained release rate than achieved here
is necessary for continuing spermatogenic suppression and support of sexual interest
in normal men.
The inconsistent suppression and variable recovery of spermatogenesis in the MENT
group was accompanied by an increase in FSH with no significant change in LEI or
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testosterone concentrations during the second half of the treatment period. Both
gonadotropins are required for normal spennatogenesis [43, 44],and recent data from
analysis of testicular biopsies following gonadotropins suppression and selective
replacement with hCG or FSH has indicated specific sites of action in stimulating
spermatogenesis [302]. Measurement of intratesticular testosterone concentrations
and of the specific testicular androgen epitestosterone during administration of male
contraceptive regimens has shown that testicular steroidogenesis is incompletely
suppressed [31, 201, 303]. It appears that the rise in FSH seen here with low but
detectable LH concentrations is sufficient to support normal spermatogenesis in
some men, emphasising the need for maximal suppression of both gonadotropins and
thus depletion of intratesticular testosterone for optimal spermatogenic suppression.
It is of note however that both men who withdrew from the study because of reduced
sexual interest and function did so after only 8 weeks treatment, thus even the peak
serum MENT concentrations were insufficient in these normal men. This contrasts
with other evidence that the MENT dose was not insufficient, as haemoglobin
concentration was in fact increased at 12 weeks and HDL-C was reduced, whereas in
the testosterone group both these biochemical variables were unchanged, with no
evidence of inadequate behavioural support. This discrepancy may indicate that a
relatively higher dose of MENT is required for behavioural support in normal men
compared to hypogonadal men [76, 231] and also compared to trophic effects on the
bone marrow and liver, which may reflect its restricted metabolism.
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Spermatogenic suppression continued in the testosterone group beyond 12 weeks
treatment, with all men eventually becoming azoospermia However this required
more than 24 weeks treatment, and overall was very similar to previous data using
the same dose of etonogestrel but with a lower dose of testosterone [220]. This
contrasts with improved suppression using the lower dose of testosterone but higher
dose of etonogestrel [273], In these earlier studies there was no evidence of
inadequate androgen replacement with these combinations and there were only
minimal non-reproductive side effects on lipoprotein metabolism and weight.
Together these data illustrate dosage effects for both the testosterone and
progestogen component and demonstrate the importance of the progestogen dose
compared to the testosterone dose in maximising spermatogenic suppression.
Disadvantageous effects of this increased dose of testosterone were exemplified by
the progressive increase in haemoglobin and decrease in HDL-C concentrations,
which were not seen in our previous studies using a lower dose of testosterone
(400mg/12 weeks) despite average testosterone concentrations being similar to pre-
treatment over the second 24 weeks of treatment. Further evidence for the dose of
testosterone being supraphysiological is the small but significant increase in the size
of the prostate. These results are in keeping with the physiological replacement dose
of testosterone being nearer 5 than 7 mg/day [303] and highlight the importance of
measuring the response of androgen-dependent variables such as haemoglobin
concentration and haematocrit to determine the optimum replacement dose rather
than solely serum testosterone which will be overestimate pre-treatment if only
morning sampling is used [291].
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The major potential advantage of MENT is that it is resistant to 5a-reduction and
may therefore relatively spare the prostate. This is supported by data from non-
human primates [294] and hypogonadal men [76], The present data also support
this, with a fall in serum PSA with a non-significant fall in prostate volume in the
MENT group, The lack of change in prostate volume may reflect the relatively
young age of the study population and the short duration of treatment, and both
results are very similar to those previously reported in similarly-aged hypogonadal
men [76]. This interpretation must be tempered however by the above reservations
regarding the overall adequacy of the dose ofMENT administered.
Maintenance of bone mass in men is dependent on serum testosterone and the local
conversion by the enzyme aromatase to estradiol [304], MENT is also a substrate for
aromatase, but in hypogonadal men 2 MENT implants did not appear sufficient to
maintain lumbar spine bone mass [76]. The present data do not show any evidence
for loss of bone mass in the MENT group over this relatively short duration of
treatment. This may reflect differences between normal and hypogonadal men, or
the additional administration of the progestogen.
There was a small but significant elevation of systolic blood pressure in the MENT
group. There was no change in diastolic pressure, and no change in the testosterone
group. A similar finding was reported in a previous study investigating MENT alone
[234], The observed increase in systolic blood pressure may reflect increased arterial
stiffness. Arterial stiffness is inversely related to testosterone concentrations in older
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men [305], and systolic blood pressure is increasingly recognised to be a strong
cardiovascular risk factor [306]. Large artery stiffness was increased by induced
hypogonadism in men with prostate cancer [307] and recent data from the
Framingham Heart study suggest that endogenous estradiol may be vasculoprotective
[308], During MENT administration both testosterone and estradiol concentrations
are low. Although MENT is aromatised to an active estrogen [233], the low serum
concentrations both of MENT, and therefore of potential active metabolites may
contribute to increased arterial stiffness and a rise in systolic blood pressure.
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2.5: Conclusion
In conclusion this study demonstrates that the combination of MENT and
etonogestrel results in rapid and profound spermatogenic suppression. Formulation
of MENT to give consistent release at a dose similar to that in the initial weeks of
this study may be a promising approach for hormonal male contraception although
non-reproductive effects were detected. The testosterone group also showed rapid
spermatogenic suppression, but it is clear that even with a highly effective
testosterone/progestogen combination it is of greater value to alter the dose of
progestogen than that of the testosterone component to optimise the rate and extent
of suppression and minimise non-reproductive androgenic effects.
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Chapter 3 Study M016: Investigation of the effects of gonadotrophin
withdrawal and progestogen administration on hormone
production, metabolism and action in the human testis.
3.1: Introduction
Testicular function is dependent on trophic support from the gonadotrophins LH and
FSH. LH stimulates steroidogenesis, particularly of testosterone from the Leydig
cells, which together with FSH is necessary for normal spermatogenesis. The effects
of testosterone and FSH are mediated through the Sertoli and peritubular cells as
these cells but not genu cells express receptors for these hormones [29, 309-312],
Recently the demonstration that Sertoli cell specific knockout of the androgen
receptor results in spermatogenic arrest at the spermatocyte/spermatid stage has
provided clear evidence that androgen action via the Sertoli cell is required for
normal spermatogenesis [313]. Selective withdrawal and replacement of LH (and
thus intratesticular testosterone) and FSH in men have shown that both are required
for quantitatively as well as qualitatively normal spermatogenesis [43, 44], but the
pathways through which testosterone and FSH support spermatogenesis remain
uncertain.
Understanding of gonadotrophin-dependent pathways regulating spermatogenesis is
also important for understanding testicular mechanisms to enhance development of
novel male contraception. Gonadotrophin suppression by the administration of
testosterone alone, or with a progestogen or gonadotrophin hormone releasing
honnone (GnRH) antagonist results in suppression of spermatogenesis to
azoospermia in most men [291, 300], There is however variation in the degree of
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suppression between individuals. Some will become azoospennic with regimens that
result in incomplete suppression of spermatogenesis in others, thus studies of the
most effective regimens yet investigated generally show a small proportion of men
who do not become azoospermic [239, 250, 255], The basis for inter-individual
variation in the response to contraceptive regimens is unclear but knowledge of this
would allow more effective patient selection and drug administration. One potential
mechanism for this is variation in activity of the enzyme 5a-reductase, which
converts testosterone to the more potent androgen dihydrotestosterone (DHT) [34],
This possibility is supported by rodent data, which demonstrate a requirement for
higher concentrations of testosterone to support spennatogenesis in the presence of a
5a-reductase inhibitor [36], Two clinical studies involving administration of a 5a-
reductase inhibitor did not however provide any positive evidence in support of this
[224, 314], although the isoenzyme predominantly expressed in the testis, type 1 5a-
reductase, is inhibited to a lesser extent by the drug used (finasteride) compared to
the type 2 isoenzyme. Alternative potential mechanisms include differences in the
number of CAG repeats in the androgen receptor and polymorphisms in androgen-
related genes, although the data are inconsistent [200, 315,316].
The addition of a progestogen to a testosterone-based regimen increases
spermatogenic suppression while allowing a reduction in the dose of testosterone,
which may have safety advantages [101, 249]. Progestogens increase the speed or
degree of gonadotrophin suppression enhancing spermatogenic suppression, but
there is also indirect evidence that progestogens may also suppress spennatogenesis
by gonadotrophin-independent direct effects on the testis [201], In keeping with this,
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expression of both nuclear and novel membrane progesterone receptors has been
demonstrated in the human testis [317] and progestogens have been demonstrated to
have direct inhibitory effects on Leydig cell function in a murine cell line [318].
In this study we have investigated changes in gene expression in the human testis in
response to gonadotrophin withdrawal by administration of a GnRH antagonist with
add-back testosterone to prevent hypogonadism. The study was also designed to
investigate potential testicular effects of addition of a progestogen, and to allow
correlation of the degree of spermatogenic suppression with changes in gene
expression. Genes involved in steroidogenesis and steroid metabolism and those
expressed by Sertoli cells or germ cells at different stages ofmaturation were chosen
to investigate the various testicular compartments. Sertoli cell genes included the
androgen and FSH receptors directly relevant to Sertoli cell regulation, the FSH-
regulated gene inhibin a (although also expressed in Leydig cells) and human
homologues of the Pem gene (PEPP1 and PEPP2) identified in the mouse as highly
androgen regulated [319, 320], Germ cell genes were chosen to represent those
expressed at different stages of spermatogenesis, i.e. by spermatogonia and primary
spermatocytes (melanoma antigen family A4, MAGE A4) [321, 322], spermatocytes
(acrosin binding protein, ACRBP) [323, 324] and round spermatids (protamine 1,
PRM1) [325, 326],
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3.2: Materials and Methods
Patient recruitment
Thirty healthy men requesting vasectomy were recruited. Inclusion criteria included
age (18-50 years), no past significant medical problems, normal biochemical and
haematological parameters, normal andrological examination, sperm concentration
>20 xl06/ml and normal plasma LH, FSH and testosterone concentrations. All
subjects provided written informed consent. The study had ethical approval from the
Lothian Regional Ethics Committee and was performed according to Good Clinical
Practice guidelines.
Study design and drug treatment
The study was a randomised controlled trial of the effects of cetrorelix and
testosterone with or without desogestrel. Following satisfactory completion of
screening examination and investigations, thirty subjects were randomly allocated to
one of three treatment groups by third-party randomisation using sealed envelopes in
blocks of 10. Ten subjects were allocated to the control group and had a testis biopsy
at the time of vasectomy without study drug administration. The other 20 subjects
received both cetrorelix and testosterone injections for a four-week period prior to
testis biopsy at the time of their pre-planned vasectomy with half (10) given the
progestogen desogestrel in addition (CT and CTD groups respectively). Cetrorelix
(Cetrotide®, Serono Europe Ltd, London, UK) 3mg s.c. was administered twice each
week. Testosterone was administered as testosterone enanthate (Cambridge
Laboratories, Wallsend, UK), 200mg im on the first day of administration of
cetrorelix, and repeated 14 days later. The 10 men in the CTD group also took
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desogestrel 300pg orally (Cerazette®, 4 x 75gig, Organon NV, Oss, The
Netherlands) each day for the 28-day duration of the treatment period.
Biopsy
Testis biopsy was carried out under local anaesthetic at the time of vasectomy. The
procedure was performed through a separate incision to that for the vasectomy. The
lower pole of one testis was biopsied using two passes of a 14-gauge needle (Tru-
Cut®, Allegiance Healthcare Corporation, USA) using a previously reported
technique [327], Tissue samples were immediately frozen in a dry-ice ethanol bath
and stored at -80 °C prior to analysis. Due to the nature of the biopsy, specimens
were not suitable for histological examination. Subjects were required to apply
pressure to the scrotum for 30 minutes following the procedure and were given 2
prophylactic doses of ciprofloxacin 500mg. All subjects were reviewed 24 hours and
2 weeks following the procedure.
Isolation ofRNA and synthesis ofcDNA
Total RNA was extracted using the Qiagen RNeasy Mini kit. High RNA quality
(RIN >6.5) was confirmed by running 1 pi of a 1/10 dilution of each on RNA 6000
Nanochips in the Agilent 2100 Bioanalyzer (Agilent Technologies, South
Queensferry, UK). One sample from a man in the CTD group and one from the
control group were found to be of inadequate quality and was not analysed further.
First strand cDNA (+/- Reverse Transcriptase) was synthesised from 3pg of total
RNA as described previously [328].
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Real Time Quantitative PCR
Quantitative real time RT-PCR was performed using the Lightcycler (Roche
Diagnostics, East Sussex, UK) as described previously [329]. Reverse transcribed
RNA samples were diluted 1/25 in nuclease-free water (Promega Ltd., Southampton,
UK). 1 pi diluted first-strand cDNA was added to a final volume of 10 pi containing
50pg/ml BSA and 0.5 pM each of forward and reverse primer in 1 x Platinum SYBR
Green qPCR SuperMix UDG (Invitrogen, Paisley, UK). Amplification was
continued for 45 cycles with signal acquisition after each round of extension.
Following amplification, continuous melt curve analysis was performed to ensure
product accuracy and samples were analysed by agarose gel electrophoresis (data not
shown) to confirm product size. Primers for each gene are given in Table 1 and were
either previously published as indicated or designed using online Primer3 software.
Standard curves for each PCR were derived by making a series of dilutions (1/10 to
1/10000) of first-strand cDNA from one of the control group of samples, as
previously described [328]. The dilutions yielded a straight line for each product.
The slopes of these curves are a measure of the efficiency of the PCR (E=101 ~slopc),
which gave an amplification rate of 1.6 to 1.9- fold per cycle for each product. For
each experiment, amplification reactions were performed in duplicate for every
cDNA sample used. Calculations for each mRNA concentration were made relative
to RPL32 from the same sample to allow comparisons between biopsies. RPL32,
which encodes a ribosomal protein, proved to be the most consistent reference gene
for these samples although GAPD and B2M [330] yielded similar results.































































































determining the actual amount of amplification required to yield a signal for each
target [331,332],
Semen Analysis
Sperm concentration in the ejaculate was measured in all subjects on one occasion
prior to inclusion in the study and again on the day of vasectomy, in both cases
following 3-7 days abstinence. Concentration was assessed using World Health
Organisation methodology [299], Azoospermia was confirmed by thorough
examination of the pellet following centrifugation of the whole semen sample.
Hormone Assay
Blood samples were obtained pre-treatment and on the day of vasectomy for all
subjects. An additional sample was taken from the men in the two treatment groups
after 14 days drug administration, immediately prior to second injection of
testosterone enanthate. Following centrifugation, serum was stored at -20°C until
assay. Testosterone was measured by radioimmunoassay [335] and FSH and LH by
time-resolved immunofluorometric in-house assay [273], Assay sensitivity was 0.3
nmol/1 for testosterone, 0.03 IU/1 for FSH and 0.15 IU/1 for LH. The intra-assay
coefficients of variation (CVs) were <10% in each case, and all samples were
analysed in single assays.
StatisticalAnalysis
Results are presented as mean ± SEM. Hormone and sperm data were compared
using paired or unpaired t-tests as appropriate after cube-root and log transformation
99
respectively. Treatment effects on gene expression data were initially compared by
ANOVA (3 groups) or unpaired t test (2 groups). Where ANOVA suggested
significant treatment group effects, this was further investigated by unpaired t tests.
For all comparisons a P-value of <0.05 was considered significant.
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3.3: Results
Subjects, withdrawals, adverse events
Thirty men (mean age 38 years, range 30-47 years) were recruited to the study.
There were no significant differences between treatment groups in age or pre-
treatment sperm and reproductive hormone concentrations (table 2). One subject
randomised to the control group withdrew from the study for personal reasons, thus
29 men underwent testis biopsy (figure 1). There were no significant adverse events.
Two subjects complained of itching/redness at the site of cetrorelix injections and
one subject in the CTD group reported mood swings and hot flushes during the
treatment period.
Control (n=9) CT group
(n=T0)
CTD group (n=10)
Age (years) 39.8 ± 1.75 35.8 ± 1.16 39.8 ± 1.21
Sperm concentration (mill/ml) 66.6 ± 18.5 47.5 ±8.2 59.9113.8
LH (IU/1) 4.8 ±0.65 4.5 ±0.38 4.1 ±0.46
FSH (IU/1) 4.610.83 4.5 ±0.5 5.1 ±0.91
Testosterone (nmol/1) 18.2 ± 1.8 19.812.3 20.7 ± 1.9
Table 2. Pre-treatment hormone data presented as mean ± SEM
Hormones
Gonadotrophin concentrations were markedly suppressed in all men in both
treatment regimens at 14 days and then after 28 days, at the time of testicular biopsy
(P<0.001, figure 2a and b). There were no differences in the concentrations of either
LH or FSH between the CT and CTD groups at either time point. FSH was
suppressed to the limit of detection or close to it in all men. LH was suppressed to
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269 men approached
1 withdrawal 29 completed
Figure 1. Study treatment pathway. Four subjects failed screening: 1 for high








screening day 14 day28
(b)
Figure 2. Serum concentrations of LH (a) and FSH (b) in untreated controls (white bars)
and men receiving cetrorelix and testosterone (CT group black bars) or cetrorelix,
testosterone and desogestrel (CTD group grey bars). Results as means ± SEM, n = 8-10
per group.
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0.52±0.09 IU/L and 0.51±0.07 IU/L in the CT and CTD groups respectively at the
time ofbiopsy.
Mean testosterone concentrations remained in the normal range in the two treatment
groups although were slightly reduced at 28 days (figure 3) in keeping with the
administration schedule, as this was the point of trough concentration after the
second injection. There were no significant differences in testosterone
concentrations between the 3 groups either pre-treatment or at the time of testis
biopsy.
Sperm Concentrations
Pre-treatment sperm concentrations were normal in all subjects. Profound
suppression of sperm concentration was seen in both treatment groups within the 28-
day treatment period (figure 4). Mean concentrations fell to 17.8±9.2 xl06/ml in the
CT group, and to 8.1±4.1 xl06/ml in the CTD group compared to 47.5±8.2 and
59.9±13.8 xl06/ml in the two groups pre-treatment. However, there was some inter-
individual variability with 3 subjects in the CT group and 2 in the CTD group
maintaining sperm concentrations in the normal range (>20 xl06/ml) at day 28,
whereas sperm concentrations were less than 5 xl06/ml in all others, and one man in
each group had become azoospermia This allowed classification of 'suppressors' vs
'non-suppressors', the former having sperm concentrations <5 xl06/ml after 4 weeks
treatment, the latter having normal sperm concentrations at that time.
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Figure 3. Serum concentration of testosterone in untreated controls (white bars) and men
receiving cetrorelix and testosterone (CT group black bars) or cetrorelix, testosterone and
desogestrel (CTD group grey bars). Results as means ± SEM, n = 8-10 per group.
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Figure 4. Sperm concentrations in untreated controls (white bars) and men
receiving cetrorelix and testosterone (CT group black bars) or cetrorelix,
testosterone and desogestrel (CTD group gi'ey bars). Results as means ± SEM,
n = 8-10 per group.
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Testicular Biopsy Results
Testicular tissue specimens were analysed by treatment vs. control and by treatment
group, and also by the degree of spermatogenic suppression. Candidate genes were
divided into three groups on the basis of their testicular compartment, ie
steroidogenic/steroid metabolism genes expressed in Leydig cells, Sertoli cell
markers, and those specific to developing germ cells. The overall results are
summarised in table 3.
Genes Controls CT CTD
CYP17 27.37 ±4.82 0.93 ±0.21 0.9 ±0.22
5aR1 0.3 ±0.04 0.23 ±0.02 0.17 ± 0.02
3bHSD 0.2 ±0.03 0.05 ±0.01 0.04 ±0.01
AMH 0.01±0.0 0.004 ±0.0 0.004 ±0.0
INHa 38.55 ±9.77 18.97 ±3.5 16.05 ±3.37
AR 1.11 ±0.13 1.22 ±0.11 1.06 ±0.12
FSHR 0.22 ±0.03 0.18 ±0.02 0.24 ±0.06
hPEPPI 1.09 ±0.17 0.82 ±0.09 1.02 ±0.07
hPEPP2 16.39 ±2.9 12.20 ±1.68 10.67 ± 1.16
MAGEA4 0.47 ±0.1 0.35 ±0.08 0.25 ±0.05
PRM1 2388.7 ±381.87 2422.01 ±387.88 1818.86 ±452.22
ACRBP 133.37 ±10.96 105.95 ± 13.4 81.19 ± 12.81
Table 3. Mean gene expression of the three groups as a % relative to RLP32 ± SEM
Steroidogenic Genes
The two genes expressing the steroidogenic enzymes steroid 17-alpha-
hydroxylase/17,20 lyase (CYP17A1) and 3 flhydroxysteroid dehydrogenase
(HSD3B2) showed markedly reduced expression in both treatment groups (both
p<0.0001), to approximately 3% and 25% of the control group respectively (figure
5). This effect was similar in the two treatment groups. Expression of 5a-reductase
type 1 (SRD5A1) was also reduced in both treatment groups overall compared to












Figure 5. Expression of steroidogenic genes CYP17A1, HSD3B2 and SRD5A1 in
controls (white bars) and men in CT (black bars) and CTD groups {striped bars).
Results are means ± SEM, n = 8-10 per group. Gene expression relative to RLP32.
* PO.OOlvs controls.
108
in the CTD group (57% of control, P=0.0065) whereas gene expression in the CT
group was not significantly lower than controls (77%, P=0.1). There was also a
significant difference in SRD5A1 gene expression between the CTD and CT groups
(P=0.02).
Sertoli Cell Genes
Expression of inhibin a subunit (INHA) was reduced in both treatment groups
together (P=0.007, figure 6) but this was more marked in the CTD group (42% of
control, P=0.037), with the difference between the control and CT group not quite
reaching statistical significance (49% of control, P=0.056). There was no significant
difference between the CT and CTD treatment groups. There were no differences in
expression of the genes encoding the androgen receptor (AR), FSH receptor (FSHR)
or antimullerian hormone (AMH) between the treatment and control groups.
Expression of hPEPPl was also unchanged, whereas there was a reduction in
hPEPP2 expression in the two treatment groups combined (P=0.05) which did not
reach statistical significance in either group separately (74%, P=0.2 and 65%, P=0.08
of control in the CT and CTD groups respectively).
Germ Cell Genes
Three genes specific to germ cells were investigated (figure 7). Expression of
MAGEA4 was reduced particularly in the CTD group (to 53% of control), but this
did not reach statistical significance (P=0.06) because of high inter-individual
variability. MAGEA4 expression was not reduced in the CT group (75% of control,

























Figure 6. Expression of Sertoli cell genes INHA, AR, AMH, FSHR, hPEPPl and hPEPP2 in
controls (white bars) and men in CT (black bars) and CTD groups {striped bars). Results are











Figure 7. Expression of germ cell genes MAGEA4, PRM1 and ACRBP in controls {white
bars) and men in CT {black bars) and CTD groups {striped bars). Results are means ± SEM,
n = 8-10 per group. Gene expression relative to RLP32. * P<0.01 vs controls
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Expression of ACRBP was reduced (P=0.02). Analysis by treatment group showed
that this was confined to the CTD group (61% of control, P=0.008) with no
difference between the CT and control groups (79% of control, P=0.1). Expression
in the CT and CTD groups was not significantly different.
Gene expression analysed by sperm suppression.
Subjects were classified according to the degree of spermatogenic suppression
independent of treatment group, with most men (n=14) showing marked
spermatogenic suppression (sperm concentration <5xl06/ml) even within the short
treatment interval whereas others (n=5) maintained sperm concentrations within the
normal range. There were no differences in sperm, LH or FSH concentrations pre-









pre-treatment (xl06/ml) 66 ± 16 50 ±7 64 ±24
Sperm concentration
at biopsy (x 106/ml)
75.7 ± 14 1.4 ±0.4 48 ±9
LH pre-treatment (IU/L) 4.21 ±0.61 3.46 ±0.54 3.92 ±0.68
LH at biopsy (IU/1) 3.54 ±0.45 0.53 ±0.06a 0.47 ± 0.14a
FSH pre-treatment (IU/L) 2.52 ±0.37 2.64 ±0.49 2.84 ±0.8
FSH at biopsy (IU/1) 2.34 ±0.37 0.05 ± 0.02b 0.03 ± 0b
Table 4. Reproductive parameters by spennatogenic suppression. bP<0.01,c P<
0.001 vs. controls.
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Both groups showed markedly reduced expression of CYP17A1 and HSD3B2
compared to controls (both P<0.0001) with no difference between suppressors and
non-suppressors. However expression of SRD5A1 did differ between groups, with a
significant difference between controls and suppressors (62% of control, P=0.004)
but not between controls and non-suppressors (81% of control, P=0.3, table 5) . It
would therefore be expected that there would be differences within treatment groups
by spermatogenic suppression. This was confirmed to be the case in the CT group
(suppressors 0.20±0.01 vs 0.30±0.01 in non-suppressors, P=0.002) whereas there
was no difference in the CTD group (0.17±0.03 vs 0.16±0.03 respectively).
Among the Sertoli cell genes, the reduction in INHA expression was only significant
in the suppressors (42% of control, P=0.01; 55% of control in non-suppressors,
P=0.2). hEPP2 expression was slightly reduced with borderline statistical
significance in the suppressors (73% of control, p=0.05) but not in the non-
suppressors (79% of control, P=0.4). As with the analysis by treatment group,
expression of other Sertoli cell genes investigated did not differ between controls and
either group (table 5).
Markers of spermatogenesis also showed differential changes in suppressors
compared to non-suppressors. MAGEA4 expression was only reduced in
suppressors (55% of control, P=0.02; 93% in non-suppressors, P=0.8). ACRBP
expression showed similar changes, reduced to 65% of control in suppressors
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(P=0.003) but similar to controls in the non-suppressors (89% of control, P=0.5).
PRM1 expression did not differ from controls in either group (table 5).
Gene Expression Controls Suppressors Non-suppressors
(n=9) (n=14) (n-5)
Steroidogenesis
CYP17A1 27.4 ±4.8 0.8810.18° 1.01 ±0.31°
HSD3B2 0.2010.03 0.05 ±0.01° 0.0510.01°
SRD5A1 0.3010.04 0.19 1 0.01b 0.24 1 0.04
Sertoli cell
INHA 38.619.8 16.2 1 2.4b 21.416.5
FSHR 0.22 1 0.03 0.22 1 0.04 0.1910.04
AR 1.11 ±0.13 1.0710.08 1.3610.20
AMH 0.005 1 0.002 0.00410.001 0.005 10.001
hPEPPl 1.0910.17 0.9710.07 0.75 10.11
hPEPP2 16.412.9 11.01 1.1a 12.912.4
Spermatogenesis
MAGEA4 0.4710.10 0.26 1 0.04a 0.43 ±0.16
ACRBP 133 1 11 86 1 9b 118126
PRM1 2388 1381 1985 1310 2811 ±685
Table 5. Gene expression analyzed by sperm suppression, values are gene expression
relative to RLP32 (mean ± SEM). a P<0.05, b P<0.01, c P<0.001 vs. controls
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3.4: Discussion
In this study the effects on testicular gene expression of induced
hypogonadotrophism in normal men for four weeks by administering a GnRH
antagonist plus testosterone are investigated. An additional group were administered
desogestrel to investigate the effects of testicular progesterone receptor activation in
addition to gonadotrophin withdrawal. GnRH antagonists may be of particular use in
the suppression phase of male contraceptive regimens [265], increasing the speed
and consistency of the response. While the most marked effects were on
steroidogenic enzyme expression, there was evidence of a selective reduction in the
testosterone metabolising enzyme SRD5A1 and of the spermatocyte-specific gene
ACRBP but not of genes expressed at earlier stages of spermatogenesis in those men
who were given desogestrel. The group not receiving desogestrel showed little or no
differences in expression of these genes compared to the control group despite
profound suppression of gonadotrophins and of spermatogenesis. Greater
suppression of spermatogenesis after this short duration of gonadotrophin withdrawal
was also associated with reduced expression of SRD5A1 and ACRBP, but also of
INHA, expressed by Sertoli and Leydig cells [148, 159, 336] and of MAGEA4,
which is expressed by spermatogonia and primary spermatocytes [321], PRM1,
which is expressed at later stages of spermatogenesis [325, 326], was not affected
despite the dramatic reduction in sperm concentration in the ejaculate, to
azoospermia in two men. This is consistent with data suggesting that gonadotrophin
withdrawal results in a defect in spermiation in humans [31, 39], These data
therefore provide direct evidence that progestogens have specific intratesticular
effects independent of gonadotrophin suppression, which may contribute to the
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enhanced suppression of spermatogenesis demonstrated in trials of hormonal male
contraceptive regimens [273, 274, 300, 301]. They also illustrate the value of this
approach to the study of spermatogenic suppression in response to potential
contraceptive regimens and other manipulations of testicular function.
Percutaneous biopsies of the testis using either a tru-cut device as here, or a fine 21-
gauge needle are regularly performed in the management of infertility. They are used
to retrieve spenn from patients with obstructive azoospermia for intracytoplasmic
sperm injection (ICSI) and for diagnostic purposes [327, 337-339], There were no
serious complications during this study, supporting the use of this relatively non¬
invasive technique for research purposes. However the nature of the biopsy and its
size made it unsuitable for histology or the measurements of gene products such as
testosterone or inhibin.
Gonadotrophins, Testosterone Levels, and Sperm Concentration
The treatment regimen resulted in suppression of gonadotrophins while maintaining
normal peripheral testosterone concentrations. The profound and similar
gonadotrophin suppression between those men receiving cetrorelix with testosterone
and those additionally receiving desogestrel allows the identification of testicular
effects of desogestrel although it is possible that there was a slightly greater
suppression of gonadotrophin secretion in the CTD group that we were unable to
detect. Detailed analysis of the relationships between gonadotrophins and
spermatogenic suppression has demonstrated that LH but not FSH concentrations
predict ongoing low rates of spermatogenesis [201] and that progestogens, including
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desogestrel as used here, have additional gonadotrophin-independent effects.
Spermatogenesis was also rapidly suppressed in both treatment groups, also to a
similar degree in the two treatment groups. There are limited data on the use of
GnRH antagonists to suppress spennatogenesis, but these results, albeit of only short
treatment duration, provide support to suggestions that they are highly effective at
inducing gonadotrophic and spermatogenic suppression [264-266, 340], While most
men showed profound suppression of spermatogenesis after only 4 weeks of
treatment, some 25% still had sperm concentrations in the normal range. It is likely
that these men would have subsequently also shown profound suppression, but our
short term study allowed a clear distinction between those showing a rapid response
(here termed 'suppressors') and those maintaining spermatogenesis at that stage of
treatment ('non-suppressors'). These non-suppressors should not be regarded as
necessarily having the same characteristics as those who continue to show low rates
of spermatogenesis despite more prolonged gonadotrophin withdrawal, but provide a
useful group for the investigation of variation in the initial stages of spermatogenic
suppression.
Steroidogenic Genes
The most striking changes in gene expression during gonadotrophin withdrawal were
in the steroidogenic enzymes CYP17A1 and HSD3B2, with CYP17A1 reduced to
<5% of expression in control men. There was no evidence for an additional effect of
desogestrel, and no relationship to degree of suppression of spermatogenesis. In
rodents Cypl7al and Hsd3b2 expression appears unrelated to LH during fetal
development [341]. In adult animals however, primary control of both enzymes is via
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the LH receptor [48, 342], These data suggest a similar mechanism of regulation
occurs in humans. Progestogens have also been reported to have direct effects on
LH receptor expression and to inhibit steroidogenesis in murine Leydig cells [318],
but the present results do not provide evidence that such regulation occurs in humans
with desogestrel at the dose used here. It is however possible that the very marked
degree of suppression of CYP17A demonstrated here has prevented detection of an
additional progestogenic effect.
The enzyme 5oc-reductase converts testosterone to the more potent androgen DHT.
This amplification of androgen action has been suggested to be of importance in the
testis in states of testosterone depletion, eg following gonadotrophin suppression, and
to be a mechanism whereby some men may maintain low rates of spermatogenesis
during contraceptive studies [34, 343], This has been supported by experimental
data in rodents but not by clinical studies involving inhibition of 5a-reductase [36,
314, 344, 345]. In those clinical studies however the type II isoenzyme was
preferentially inhibited by the drug finasteride. 5a-reduced steroids within the testis
are relatively resistant to gonadotrophin withdrawal [31, 346], Progesterone and
synthetic progestogens have been reported to inhibit 5a-reductase activity in skin
[347-349], which predominantly contains the type 1 isoenzyme. The present data
demonstrate that SRD5A1 1 gene expression was reduced by administration of
desogestrel, but not by gonadotrophin suppression alone. SRD5A1 expression was
also reduced in relation to the degree of suppression of spermatogenesis. This was
clearly the case in men in the CT group, but no difference by spermatogenic
suppression was observed in the CTD group. This may reflect the already-present
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inhibitory effect of desogestrel, but analysis is also limited by the small group sizes.
These data therefore add to the evidence implicating 5a-reduction as a key pathway
in the testicular response to hormonal contraceptive regimens, particularly those
based on co-administration of a progestogen.
Sertoli Cell Genes
The FSH receptor is only expressed in the Sertoli cells in the testis where FSH acts
with testosterone to support spermatogenesis. Withdrawal of FSH and suppression of
intratesticular testosterone concentrations induced by the treatment regimens used
here might be expected to have marked effects on Sertoli cell function, manifesting
as changes in gene expression. However the only Sertoli cell gene demonstrated to
change was INHA (encoding inhibin a), which was reduced in both treatment
groups. This fall was relatively modest, and was statistically significant only in the
CTD group. Additionally, analysis by degree of sperm suppression showed lower
INHA expression only in the responders group. This may indicate both a direct
effect of progestogen on Sertoli cell function in keeping with the expression of
progesterone receptors by human Sertoli cells [317] and a relationship with
spermatogenesis. Inhibin B is the biologically active form of inhibin in men
consisting of a dimer of the a and [3 B subunits, and its concentration in blood
quantitatively reflects spermatogenesis, comprising the feedback loop linking the
functional activity of the seminiferous epithelium with FSH secretion [145, 160,
350], FSH administration increases inhibin B secretion in hypogonadal but not
normal men [149, 351, 352] and there is clear evidence in rodents that inhibin a
gene expression is FSH dependent [353, 354], Similarly FSH administration
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increases a subunit concentrations in blood, as does hCG, which may indicate a
contribution from Leydig cells [149, 355] which also express INHA [148, 159, 336].
Gonadotrophin withdrawal in men results in a fall in serum inhibin B but only to
approximately 50% of normal, even with prolonged treatment [153]. This appears to
match the magnitude of the change in gene expression observed in the present study,
consistent with the remaining 50% of inhibin expression and production being
gonadotrophin-independent in normal men, once spermatogenesis has been
established during normal puberty.
Despite the degree of gonadotrophin withdrawal and fall in sperm production
induced by these treatment regimens, there were no changes in expression of the
other Sertoli cell genes investigated. In particular, we investigated the PEPP1 and
PEPP2 genes, as these are the human homologues of the murine Pem gene. Pem
expression is highly androgen-dependent [313, 320], thus we hypothesised that
expression of its human homologues would be reduced under the experimental
conditions here. These data confirm that PEPP1 and PEPP2 are expressed in the
human testis, and that the expression of PEPP2 but not PEPP1 was reduced in treated
men compared to controls. Expression of PEPP2 was also reduced in the
spermatogenic responder group, but not in non-responders. These data are consistent
with PEPP1 expression being androgen-dependent as with Pem in the mouse,
although the degree of androgen-dependency appears much less in the human.
Expression of rat Pem in the testis is also less androgen-dependent than in the mouse
[319] emphasising the importance of species specificity in the regulation of testicular
function.
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Expression of other Sertoli cell genes investigated, i.e. FSHR, AR and AMH was
similar in controls and treated groups, indicating that expression of these genes is not
gonadotrophin dependent, nor does expression appear closely linked to normal
spermatogenesis. FSHR expression is FSH-regulated in the mouse [356], but these
data suggest that this is not the case in the human. AMH production is low post
puberty and suppression is predominantly maintained by high intratesticular
testosterone concentrations [182, 188] with additional regulation by germ cells at
some stages of development [357]. AMH gene expression was confirmed to be very
low in these biopsies of normal men. An increase in AMH might have been
observed following gonadotrophin withdrawal, but was not seen in the relatively
short period of study.
Germ Cell Genes
MAGE-A4 is expressed by spermatogonia and primary spermatocytes but not by
spermatids or Sertoli cells [321] and is therefore a marker for early spermatogenesis.
We also investigated expression of ACRBP as a further spermatocyte-specific
marker [323, 324], MAGEA4 expression was similar in the control to the two
treatment groups, but was reduced in the responder group. ACRBP showed greater
changes, being reduced in the CTD but not CT groups compared to controls,
indicating a direct effect of the progestogen. As with MAGEA4, there was markedly
lower ACRBP expression in those men in the responder group, but not in non-
responders. The greater changes in ACRBP than MAGEA4 may reflect greater
changes in spermatocytes than spermatogonia. This is consistent with data from
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stereologic analysis of testis biopsies [31] following similar treatment regimens to
that used here. Those data indicated that after only 2 weeks of
testosterone/progestogen treatment there were fewer type B spermatogonia and early
spermatocytes present in the seminiferous epithelium, with inhibition of
spermatogonial maturation. This effect was less marked in men treated with
testosterone alone, who showed slower gonadotrophin suppression, and with longer
treatment durations marked changes were seen in both treatment groups in all genu
cell types. Changes in gene expression in spermatogonia and spenuatocytes can
therefore occur rapidly following gonadotrophin withdrawal and are associated with
more rapid suppression of spermatogenesis.
In contrast to these changes in markers of early and mid stages of spermatogenesis,
there were no differences in expression ofPRM1 either by treatment group or by rate
of spermatogenic suppression. PRM1 is expressed in post-meiotic haploid spermatids
[326], and is necessary for fertility [358]. Expression (relative to the related gene
PRM2) is reduced in infertile men [359]. The maintenance of PRM1 expression here
is striking considering the dramatic reduction in sperm output in most men in the
treatment groups. These data therefore strongly support the observation that one of
the major early defects in the human spermatogenic epithelium following
gonadotrophin withdrawal is an inhibition of spermiation [31, 346]. This will result
in retention of the cell types expressing PRM1 while at the same time drastically
reducing sperm output. This is similar to that observed in the macaque monkey and
rodents, in which gonadotrophin withdrawal also results in retention of elongate
spermatids [3, 360], With longer gonadotrophin withdrawal all spermatogenic cell
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types are reduced [31], and would be expected to result in a decrease in PRM1
expression, but the short duration of treatment investigated here has allowed
demonstration of further evidence of the importance of spermiation failure as a
component of the mechanism by which gonadotrophin suppression results in very
rapid falls in sperm output in men. It also is in keeping with the rapid return of




These data demonstrate the value of a novel approach to the investigation of the
regulation of testicular function in men. Direct evidence for progestogenic effects on
all three major compartments of the testis, ie steroidogenesis (5a-reductase), Sertoli
cell function (inhibin a) and spermatogenesis (ACRBP), independent of
gonadotrophin inhibition is presented. Furthermore, relationships between expression
of these and other genes (PEPP2 and MAGEA4) with the rate of initial suppression
of sperm output were identified. Notably, these data provide further support for the
importance of 5a-reduction and disruption of spermiation as important components
of the testicular response to gonadotrophin withdrawal, of direct relevance to
understanding of testicular function and the development of novel methods of male
contraception.
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Chapter 4: Study M017: A single centre study comparing the 24 hour
testosterone concentration in two groups of men: men receiving a
hormonal contraceptive regimen and a control group.
4.1: Introduction
Diurnal variation of serum testosterone concentration in adult men with a peak in the
morning and a nadir in the early evening has been described in many studies [55, 362-
365], although its physiological significance, if any, is not understood. Increased
understanding of the pattern of testosterone production and thus the correct dose
required for physiological replacement will benefit those on long-term testosterone
replacement and may aid in the development of male hormonal contraception. Both
supraphysiological and subphysiological doses may have adverse effects reflecting the
very widespread distribution of androgen receptors. Supraphysiological doses of
testosterone are associated with raised haematocrit, decreased HDL levels and an
increase in mean blood pressure [366] whereas inadequate replacement results in
anaemia, osteoporosis and loss of libido [75, 79, 110].
In this study we re-examined the diurnal variation of testosterone in normal men, and
included analysis of both gonadotrophins as main drivers of testicular function, and of
inhibin B as the non-steroidal feedback loop from Sertoli cell to the pituitary gland. We
have also examined diurnal variation in a further group of normal men after
administration of a combination of testosterone and progestogen to suppress
gonadotrophin secretion using a dose of testosterone calculated to approximately match
physiological production. In this situation the testosterone is delivered constantly
throughout the 24 hours so that any variation in its concentration would represent a
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change in its metabolic clearance. As circulating testosterone is exogenously derived
under those circumstances, we have measured excretion of the specific testicular steroid
epitestosterone as a marker of ongoing steroidogenesis in the testis. These data suggest
that even without LH stimulation there is a diumal variation to testicular
steroidogenesis, and that under both normal and suppressed states there is a diurnal




Ten subjects were recruited from the general population to act as controls. Inclusion
criteria included age 18-50, BMI 18-32 kg/m , normal physical including andrological
examination, normal haematological and biochemical parameters and reproductive
hormones. Ten subjects (the treated group) were also recruited from a male
contraceptive trial (as described in Chapter 2). They received a regime of two
etonogestrel implants (each 68mg, Implanon®, Organon NV, Oss, The Netherlands)
administered sc into the upper non-dominant arm, in combination with 600mg
testosterone pellets (3 x 200mg, Organon NV) administered sc into the lower abdomen.
The testosterone implants were repeated every 12 weeks. The investigation was
performed midway between the insertion of the testosterone implants i.e. 18 weeks (+/-
7 days) after the administration of etonogestrel. All subjects gave written informed
consent, the study received approval from the local ethics committee and was performed
according to GCP guidelines.
Study Design
Each of the 20 subjects was admitted for 24 hours from 8.00am to the Welcome Trust
Clinical Research Facility at the Royal Infirmary of Edinburgh. On admission an
indwelling catheter was inserted into a vein in the forearm. Samples of blood (9ml)
were collected every hour for the next 24 hours, each sample was centrifuged, separated
and serum stored at -20C until hormone assay. Subjects emptied their bladders at 9 am
and urine samples were collected at 1pm, 5pm, 9pm, lam, and 9am, i.e 4 hourly through
the day and 8 hours overnight. A record of the total urine volume was kept for each
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time-point and aliquots of urine were stored at -20°C. Subjects were allowed to move
around freely and retired to bed by 1 am.
Assays
All hourly blood samples were analysed for testosterone, LH, FSH, Cortisol and
prolactin, and for SHBG 3-hourly. Testosterone and Cortisol were analysed by
radioimmunoassay [335], and LH FSH and SHBG by time-resolved
immunofluorometric assay. Assay limits of quantification were 0.3 nmol/1 for
testosterone, 0.5 nmol/1 for SHBG, 0.03IU/1 for FSH and 0.15 IU/1 for LH. The intra-
assay coefficients of variation (CVs) were <10% for testosterone (6.4% between 5 and
lOOnmol/L), FSH and LH, and 4% for SHBG. The inter-assay CVs were 12.4% for
testosterone, <10% for FSH and LH and 8.8% for SHBG. Inhibin B was assayed as
previously described [159, 296] with an assay sensitivity of 7.8pg/ml. Testosterone and
epitestosterone were measured in urine samples by gas chromatography-mass
spectrometry as described and validated previously [367]. For urinary epitestosterone
(aglucone plus free fraction) the interassay CV was 13.4% at 1.5 pg/L, the limit of
quantification, falling to <10% for concentrations between 10 and 38 pg/L.
StatisticalAnalysis
Hourly blood data for each subject were analysed by cosinor methods [368] fitting a
two-parameter sine curve with 24-hour periodicity. This gave an estimate of the mesor
(mean level), acrophase (time of peak level) and amplitude (difference between peak
and mean level) as well as a test of significant periodicity for the data from each subject.
Throughout the results and discussion mesor is referred to as mean and acrophase as the
128
mean peak. Rayleigh tests [369] were then used in each of the two treatment groups
separately to test for significant directionality in the acrophases, and the estimates of
mean and amplitude were compared between the treated and control groups using two-
sample t-tests.
Analysis was carried out on the logarithms of the urine measurements since they were
positively skewed. Two-factor analysis of variance was used to test for significant daily
variation in mass per hour between the five time intervals, and measurements over each
time interval were compared between treatment groups by two-sample t-tests.
Repeated measures analysis of variance was used to test whether the diurnal variation




All 20 subjects were fit and healthy, mean age of controls 29 years (range 24-43) and
mean age of the treated group 35 yrs (range 25-50). There were no abnormalities found
on biochemical and haematological screening including reproductive hormones and
andrological examination and no pre-treatment differences between the two groups (see
table 1).
Control Group Treatment Group
Age (years) 29.2 ±2.07 34.9 ±2.23
Serum LH (IU/1) 4.62 ±0.57 4.14 ±0.41
Serum FSH (IU/1) 3.41 ±0.43 2.43 ± 0.64
Serum T (nmol/1) 23.3 ± 1.99 23.78 ±3.52
Table 1. Screening values for all subjects data presented as mean ± SEM
Serum Testosterone
Serum testosterone results at the time of 24 hour sampling were similar for the two
groups with no significant differences seen in mean concentration (control mean= 16.2
± 1.5 nmol/L, treated mean=13.9 ±1.7 nmol/L, figurel). When grouped, mean
testosterone concentrations (figure la) showed a rise in concentration of testosterone in
the early morning in the control group but no such overt variation in the treated group.
However analysis of individuals demonstrated evidence of periodicity for a substantial
proportion of the individual subjects in both groups. There was significant directionality
in the mean peaks in the control group (P<0.01) with a mean peak at 7am. In contrast
although there were individual variations in the concentration of testosterone in the
treated group with mean amplitude similar to that in the control
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Figure 1. Serum testosterone concentrations over 24 hours in the control (blue) and
treated groups (red) presented as mean ± SEM.
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group (control 3.6 ± 0.54 nmol/L, treated 2.5 ± 0.4 nmol/L, NS) there was no clustering
and therefore no significant diurnal variation.
Gonadotrophins
The control group LH results demonstrated a mean LH of 3.1 ± 0.6 IU/1 (figure 2a).
Although only 3 of the men in this group showed significant periodicity, there was a
significant directionality in the peak times (P<0.01) with an amplitude of 0.58 IU/1 and
a mean peak at 5am. FSH results for the control group were within the normal range
throughout the 24-hour period (figure 2b) with a mean FSH of 1.7 ± 0.3 IU/1. 5 men
showed significant periodicity with an amplitude of 0.21 ± 0.03 IU/L but with no
significant directionality. Subjects in the treated group demonstrated highly suppressed
LH and FSH as expected with this testosterone/progestogen regime with a mean LH of
0.33 ± 0.06 IU/1 (p<0.001 vs control group) and mean FSH of 0.06 ± 0.02 IU/1
(p<0.001) and no significant variability throughout the 24-hour period for either
hormone.
Inhibin B
Significant periodicity in inhibin B was detected in 5 of the men in the control group,
but there was no evidence of directionality. Overall mean inhibin B concentrations were
lower in the treated group (control mean= 140.1 ± 3.9, treated mean=94.2 ± 2.4, P<0.01,
figure 3) but 9/10 men in this group showed significant periodicity albeit with lower
amplitude than in the controls (treated amplitude=13.1, control amplitude=30.7,
P<0.01). Additionally, the treated group demonstrated synchronised
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Figure 2. Serum concentrations of (a) LH and (b) FSH over 24 hours in the control
(blue) and treated groups (red). Mean ± SEM. The control group showed significant
diurnal variation in LH but not FSH (PcO.Ol).
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Figure 3. Serum concentrations of inhibin B over 24 hours in the control (blue) and
treated groups (red). Mean ± SEM. The treated group showed significant diurnal
variation (P<0.05) which was not seen in the control group.
134
diurnal variation with significant directionality of the peak times (P<0.05) with a mean
peak at 1.13pm.
Urinary Testosterone and EpiTestosterone
Despite the similarity in serum testosterone concentrations between the two groups,
urinary excretion was higher in the treated group overall (P<0.001) and at all time
points (figure 4a and b). There was no significant variation between the samples at
different time points in either group, thus urinary testosterone concentrations did not
demonstrate significant diurnal variation in either group.
The urinary excretion of epitestosterone (expressed as mass/hr) was 10 fold higher in
controls than in the treated group (figure 4c and d). There were therefore highly
significant differences (P<0.001) between the two groups for each of the five time
periods. There was however also significant variation between time points within both
groups (both P<0.05) with no significant difference between the groups in the pattern of
variation over the five time intervals. Thus both groups showed diurnal variation in the
excretion of epitestosterone with highest excretion in the morning sample.
Sex hormone binding globulin
SHBG concentrations were higher in the controls than in the treated group (mean 24
hour concentrations 23.6 ± 2.5 vs 17.6 ± 3.3 nmol/L, P<0.001) but showed no diurnal
variation in either group. Calculated free testosterone [370] however was similar in the
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Figure 4: Urinary excretion of testosterone (a and b) and epitestosterone (c and d)
over 24 hours in the control (filled symbols) and treated groups (open symbols), both
steroids in ng/hr. Time intervals as indicated on abscissa. Mean ± SEM.
Testosterone excretion did not show significant diurnal variation in either group, but
there was significant diurnal variation in epitestosterone excretion in both control
and treated groups (P<0.05 in both cases)
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Cortisol
Serum Cortisol concentrations in both groups demonstrated highly significant diurnal
variation with the mean peak mid morning at10am (P<0.001 controls, P<0.01 treated,
figure 5). There was no significant difference in amplitude between the two groups
(control amplitude=28.2 ± 1.96, treated amplitude=22.5 ± 3.98) There was a slight
difference in average Cortisol concentrations between the group (control 47.2 ± 2.0
ng/ml, treated 31.3 + 1.9 ng/ml P<0.05).
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Figure 5. Serum concentrations of Cortisol over 24 hours in the control (blue) and
treated groups (red). Mean ± SEM. Both groups showed significant diurnal variation
(PcO.OOl control, P<0.01 treated groups).
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4.4: Discussion
Previous studies have described the diurnal variation of testosterone in healthy men, but
none have closely examined the 24-hour hormone profile in men receiving exogenous
testosterone as a provisional hormonal contraceptive regimen.
We confirmed that normal men show a diurnal variation in testosterone concentrations,
with a peak in the morning (7am). Diurnal variation in serum LH was also detected in
the control group, with a peak at 5am, compatible with the influence of LH on
testosterone production in normal men. These findings are similar to those reported
previously, for both testosterone [56, 365, 371]; and LH [372, 373]. Cortisol was used
in this study as an internal control and demonstrated expected diurnal variation in both
groups across the 24-hour period with a peak mid-morning. The slightly lower
concentrations in the treated group may reflect the mild glucocorticoid activity of
etonogestrel [374],
The administration of exogenous testosterone and etonogestrel resulted in similar mean
testosterone concentrations to that in the control group. Establishing the correct dosage
of testosterone is a fundamental priority for male hormonal contraceptive development.
The mean serum T concentration observed in controls was 16 nmol/1 (i.e. approx
6ng/ml) and the metabolic clearance rate is approximatelylOOOL/day [375-377].
Therefore, production rate (metabolic clearance rate x serum testosterone concentration)
is approximately 6mg/day, as previously determined using isotope infusion [62, 199,
376]. The testosterone pellets used in this study were administered as 600mg every
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12weeks. Therefore 900mg was given in 18 weeks: i.e 50mg/week or 7mg/day, which is
thus at steady state an appropriate dose for physiological replacement.
The subjects in the treated group displayed serum testosterone concentrations within the
normal range throughout the 24-hour period and with a mean value similar to the
control group, as anticipated due to the constant release of testosterone from the pellets.
Although the concentrations varied through the study period in six out of ten of the
treated group the significant synchronised diurnal variation observed in the controls was
not seen. Thus the diurnal variation in testosterone concentrations observed in the
control group is likely to be due to a change in the secretion of testosterone by the testis
rather than an alteration in the metabolic clearance rate; if that was the case a similar
pattern should be observed in the treated group.
SHBG concentrations were lower in the treated group, as previously reported in men
treated with testosterone plus progestogens [273, 291] likely to account at least in part
for the higher urinary testosterone concentrations in those men. Serum free testosterone
concentrations were however similar in the two groups.
Epitestosterone (17a-hydroxyandrost-4-en-3-one) is an epimer of testosterone secreted
predominantly by the testis [378] which provides a measure of endogenous testicular
secretion. Urinary epitestosterone showed a comparable diurnal variation to that in
serum testosterone in the control group, with highest excretion in the morning,
providing further evidence that this reflects variation in testicular production rather than
changing rates ofmetabolism.
140
Urinary excretion of epitestosterone was markedly reduced in the treated group, as
previously reported in men administered similar testosterone/progestogen regimens
[239, 273]. This level of excretion is significantly higher than that in hypogonadal men
[378] indicating detectable ongoing Leydig cell steroidogenesis despite markedly
suppressed LH concentrations. This is consistent with measurements of testosterone in
testicular biopsies from men treated with similar regimens [31, 346] and may contribute
to the residual low rates of spermatogenesis in some men [291, 379]. There was clear
evidence of a diurnal variation in epitestosterone excretion in the treated group with
peak excretion in the morning, as in the control group. Whereas in the controls peak
testicular steroidogenesis as detected both in serum and urine may reflect the preceding
rise in serum LH, no such rise was seen in the treated group. This suggests that there is
an endogenous rhythm within the testis independent of LH although we cannot exclude
the presence minor unrecognized fluctuations or bioactivity in the markedly suppressed
levels of LH.
The excretion of testosterone in urine did not show significant diurnal variation in either
group although in the controls there was a tendency for the values to decline throughout
the day to reach their lowest value in the late evening. In contrast the concentration of
testosterone in serum peaked in the early morning and reached a nadir in the early
evening at 1900. These findings are compatible with the expected delay of a few hours
in the excretion of testosterone by the kidney. It demonstrates the relative insensitivity
of measurement urinary testosterone as an index of the hour to hour changes in the
secretion of testosterone from the testis.
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Inhibin B concentrations also showed significant periodicity and synchronised diurnal
variation with a mean peak in the early afternoon in the treated but not control group.
Inhibin B is partly but not completely under gonadotrophin control, thus prolonged
gonadotrophin suppression results in a gradual fall in the concentration of inhibin B (as
confirmed here) eventually to approximately 30% of control [147, 152, 153, 273]. A
previous study of testicular function in normal men detected a diurnal variation in
inhibin B [380], That study used a more frequent blood sampling regimen than used
here, which may have increased their ability to detect any variation. The existence of a
diurnal variation in inhibin B in normal men during gonadotrophin suppression has not
been previously reported, and as with the epitestosterone data indicates an endogenous
diurnal rhythm in the secretion by the testis. Inhibin B production by the testis is
independent in the short term of the concentration of gonadotrophins and reflects
spermatogenic activity [381]. Thus it appears that the removal of exogenous drivers and
regression of spermatogenesis has allowed the detection of an endogenous variation
which was masked in the control group with the sampling regimen used here. One
possible contributory mechanism is the interaction between Leydig and Sertoli cells,
which may also contribute to the regulation of inhibin production [382], It is noteworthy
that the observed peak in inhibin B in the treated group occurs in the early afternoon
whereas the peaks in serum testosterone and urinary epitestosterone are in the morning.
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4.5: Conclusions
These results raise further questions regarding the control of male reproductive
hormones levels over the 24-hour period and in particular indicate the existence of
significant intratesticular factors other than the gonadotrophins contributing to Leydig
and Sertoli cell function. It may well be that the testis has two intrinsic rhythms, that
driven by LH which is dominant and one which is non-gonadotrophin dependent which
can be alluded to by the inhibin B and urinary epitestosterone results in the treated
group. The nature of these factors and their mechanisms of action remain to be
determined.
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Chapter 5: Final Summary and Conclusions
The results of the three studies presented here contribute our understanding of the
basic underlying mechanisms of action ofmale hormonal contraceptives and provide
further evidence of their efficacy and safety in man.
The data from study MO 16 provides direct evidence that progestogens have specific
intratesticular effects independent of gonadotrophin suppression, which may account
for the enhanced suppression of spermatogenesis in male hormonal contraception
trial regimens incorporating these hormones [201, 249, 273],
The effective use of a GnRH antagonist in this study adds further support for the
effectiveness of these agents in conjunction with testosterone as male hormonal
contraceptives [265, 340]. However, their frequent administration regime and high
cost may prove prohibitive to their commercial development.
The most evident changes during this study were the marked suppression of the
steroidogenic genes CYP17A1 and HSD3B2 during gonadotrophin withdrawal. No
additional suppression of these two genes was demonstrated by inclusion of the
progestogen desogestrel. However, investigation of the SRD5A1 gene demonstrated
that expression was reduced by the addition of desogestrel but not by gonadotrophin
withdrawal alone. This provides novel evidence for a progestogenic effect on the
expression of 5a-reductase in the testis, which may reduce the amplifying effect of
conversion of testosterone to dihydrotestosterone and therefore contribute to greater
suppression of spermatogenesis. This data implicates the 5a-reduction pathway as a
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key mechanism in the testicular response to testosterone/progestogen combination
MHC regimes.
The changes in the gene expression of the germ cell genes also provided for some
novel observations. The changes in expression ofACRBP and MAGEA4 may reflect
greater changes in spermatocytes than spermatogonia, which are in keeping with
previous observations of stereologic analysis [31]. The maintenance of PRM1
expression was interesting considering the significant spermatogenic suppression
seen in most men even in this short treatment period. Therefore this data supports
previous studies that have demonstrated an inhibition of spermiation as a significant
early change in spermatogenic production following gonadotrophin withdrawal [31,
346]. This leads to maintenance of the cell types expressing PRM1 in association
with a substantial reduction in sperm production. This maybe one of the mechanisms
by which rapid falls in sperm output can be demonstrated after only a short time-
period of gonadotrophin suppression. After a longer period of gonadotrophin
withdrawal it would be expected that all spermatogenic cell types would demonstrate
suppression in keeping with previous observations [31].
MO 17 investigated closely the diurnal variation in testosterone and its metabolites in
normal men and men receiving a contraceptive regime. The diurnal rhythms
observed in the control group were in keeping with previous observations [56, 365,
372, 373], In the treated group it was reassuring to demonstrate that the serum
testosterone concentrations remained in the normal range throughout the 24-hour
period. Approximation of exogenous doses of testosterone to that observed naturally
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is a vital prerequisite of male hormonal contraceptive regimens. The demonstration
of diurnal variation in both urinary epitestosterone and serum inhibin B suggests that
there is an endogenous rhythm within the testis that is independent of LH control. It
is interesting to consider the mechanisms underlying this and how this relates to the
interaction between Leydig and Sertoli cells and its implications for the ongoing
development ofmale hormonal contraceptives.
Study MO15 investigated further the efficacy and safety of the synthetic androgen
MENT in conjunction with etonogestrel in comparison to a regime utilising
testosterone pellets. MENT and testosterone alone regimes have both been shown to
demonstrate effective spermatogenic suppression but the doses required to achieve
this can result in unwarranted non-reproductive effects [204, 232, 234], The release
rates of the MENT implants investigated in this study did not appear to be adequate
to maintain normal libido in the men in the study group. Initially however, the degree
of spermatogenic suppression achieved was comparable to that of the testosterone
group, but it did not continue to be sustained once inconsistent suppression of
gonadotrophins was seen. Reassuringly, we did not demonstrate any adverse effects
ofMENT on prostate activity or bone mass. Increases in haemoglobin and reduction
in E1DL-C were in keeping with previous observations [234], The observation of a
small but significant increase in systolic blood pressure in the MENT group may
have significant long-term health implications but further evidence is necessary. In
summary, MENT still has strong potential as a male hormonal contraceptive if
formulations to ensure a sustained release rate can be derived. Its non-reproductive
effects still require further clarification.
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The observations noted in the testosterone group build on data collected in previous
studies undertaken by this research group [239, 241, 273, 361], Consistent and
profound spermatogenic suppression was demonstrated with azoospermia in all men.
However, no significant advantage was demonstrated over previous regimens
investigated. The modest increase in testosterone dosage administered resulted in an
increase in haemoglobin and prostate size and decrease in HDL-C that our group had
not observed in previous regimens with a lower testosterone dose and comparable or
increased dose of progestogen. This highlights that it may be of greater benefit to
alter the progestogen dose than that of testosterone to keep to a minimum the
undesired non-reproductive effects.
Hormonal male contraceptives remain unavailable at present and it is uncertain
whether current ongoing studies will change that within the next 5 years. We should
continue to see significant advances in our understanding of androgen action in
different tissues possibly aided by the further development of synthetic selective
androgens. This will lead to greater sophistication of male hormonal contraceptives,
which can minimise safety concerns and may add to health benefits.
The recent 10th Summit meeting on hormonal male contraception has further
consolidated guidelines for the development and regulatory approval of these agents.
It is widely agreed that large-scale clinical trials are required to bring a product to the
market, and a number of specific criteria were agreed [383] :
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• It is still considered acceptable to use spennatogenic suppression as the main
end point in phase II trials and the goal should be < 1 million/ml.
• All participants should be followed after cessation of treatment until
reversibility of sperm production, to levels comparable with normal fertility
are demonstrated.
• Only men with sperm concentrations >20 million/ml should participate in
trials.
• Open-label non-comparative studies are acceptable if the endpoint is not
susceptible to bias.
• To demonstrate contraceptive efficacy, two independent phase III trials for 1
year involving 200 men/couples should be undertaken.
• For safety assurance, trials should involve at least 300-600 men for 6 months,
100 men for 1 year and at least 1500 men in total.
• Long-term safety will be addressed by post-marketing surveillance.
The main areas of focus for safety considerations remain the cardiovascular system,
prostate, bone, body composition and behavioural aspects. It is now widely accepted
that long-term safety will only be established by post marketing surveillance. There
are currently a number of phase III trials being undertaken in Europe/Asia and their
outcomes and conclusions will have a great bearing on the future of this method.
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